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The a-D-glucopyranosyl-(1?5)-substituted methyl glycosides of 3-deoxy-a-D-manno-oct-2-ulosonic acid
(Kdo), 3-deoxy-a-D-lyxo-hept-2-ulosonic acid (Kdh), and D-glycero-a-D-talo-oct-2-ulosonic acid (Ko) were
prepared using orthogonally protected glycosyl acceptor derivatives via glycosylation with a torsionally
disarmed 4,6-O-benzylidene protected triﬂuoroacetimidate glucosyl donor followed by global deprotec-
tion. The related 6-O-phosphoryl-a-D-glucopyranosyl-(1?5)-substituted Kdo and Kdh derivatives were
derived from a benzylidene-protected glucosyl intermediate using phosphoramidite and phosphoryl
chloride-based phosphorylation steps, respectively. The deprotected disaccharides serve as ligands to
study lectin binding of Acinetobacter lipopolysaccharide core oligosaccharides.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction Previously, a 28 kDa murine serum protein has been describedBacteria of the genus Acinetobacter have increasingly been
implicated in nosocomial infections which are difﬁcult to eradicate
due to resistance against major antimicrobial drugs.1 Lipopolysac-
charide (LPS)—located in the outer leaﬂet of the bacterial cell
membrane—is a major virulence factor contributing to bacterial
evasion of adaptive and innate immune responses.2 A general but
not exclusive architecture of LPS comprises a bisphosphorylated
acylated diglucosamine backbone, termed lipid A, a core region
and an antigenic polysaccharide which is the main target of
speciﬁc antibodies allowing the distinction of O-serotypes and
which is therefore called O-polysaccharide or O-antigen.3 The ﬁrst
sugar connecting the core region and the lipid A is—in general—
3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) but it may be partially
replaced by the isosteric, acid-stable 3-hydroxy-derivative D-glyce-
ro-D-talo-oct-2-ulosonic acid (Ko).4–7 In LPS from Acinetobacter hae-
molyticus NCTC 10305 in particular, a large fraction (80%)
contains Ko instead of Kdo (20%), providing the linkage to the
lipid A. In addition, the core oligosaccharide contains several
a- and b-conﬁgured glucosyl as well as two 3-deoxy-D-lyxo-hept-
2-ulosaric acid (Dha) residues (Fig. 1).which binds to the inner core region of LPS from this Acinetobacter
strain but also to oligosaccharides containing L-glycero-D-manno-
heptosyl-Kdo units.8–10 This ‘‘serum factor’’ has only recently been
recognized as mannose binding lectin-A (MBL-A). Most notably
this MBL binds to isolated LPS oligosaccharides with an unusual
high afﬁnity for the individual binding site (with ELISA IC50 values
in the mid to low nanomolar range).11 Extending our previous
studies detailing the interaction of the core region with antibodies
and lectins12–15, we have set out to prepare a ﬁrst series of
fragments of the Acinetobacter haemolyticus NCTC 10305 inner core
region in order to deﬁne the binding epitope at the molecular
level. Since Smith degradation of the isolated LPS core resulted in
ligands which were still bound by the lectin with similar afﬁnity5,
non-natural disaccharides containing 3-deoxy-D-lyxo-hept-2-
ulosonic acid (Kdh) have been prepared in addition. The synthetic
oligosaccharides serve as ligands in forthcoming binding and STD
NMR studies with C-type lectins such as human lung surfactant
protein D and mannose-binding lectins.
2. Results and discussion
2.1. Preparation of the disaccharides a-Glc-(1?5)-a-Kdo/Kdh
The glycosides were designed as methyl (Me) glycosides since
the single 1H NMR signal of the Me group serves as a suitable
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Figure 1. Structure of the deacylated inner core LPS fraction from Acinetobacter
haemolyticus NCTC 10305.6
B. Pokorny et al. / Carbohydrate Research 391 (2014) 66–81 67reference for integration of STD effects in binding studies. Thus the
previously reported Me a-Kdo glycoside 216 (easily available via
the scalable reaction of the peracetate 1 with MeOH, catalyzed
by Dowex (H+) ion-exchange resin) was employed for the prepara-
tion of the Kdo glycosyl acceptor derivative. The exocyclic 7,8-O
positions of 2 were protected by a 1,1,3,3-tetraisopropyldisilox-
ane-1,3-diyl (TIPDS) group in order to utilize its arming effect
and to provide orthogonality of ﬂuoride-induced silyl deprotec-
tion.17 Thus, by using imidazole and TIPDSCl2 in DMF at 40 C
the bis-silyl ether derivative 3 was obtained in 68% yield
(Scheme 1). In order to generate an option for eventual attachment
of the lateral Kdo unit (Fig. 1) and to also activate the 5-OH group
for subsequent glycosylation, a p-methoxybenzyl group (PMB) was
installed at position 4. The diol derivative 3 was ﬁrst reacted with
dibutyltin oxide to give the intermediate stannylene derivative
followed by treatment with PMB-chloride/tetrabutyl ammonium
iodide/DMF in toluene. As previously reported, the activated
stannylene acetal also induced formation of the corresponding
PMB ester 5 and the 1.5-lactone 6 as by-products.18 Treatment of
the mixture with sodium methoxide, however, eventually afforded
the methyl ester derivative 4 in 70% yield.O
HO
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Scheme 1. Reagents and conditions: (a) TIPDSCl2, 1H-imidazole, DMF, 40 C, 68%; (b) Bu
then (c) 0.1 M NaOMe, MeOH, rt, 70% for 4.Previously, an a-(1?5)-linked glucosyl residue had been cou-
pled to Kdo using an acetylated 2-O-benzyl thioglycoside donor
under promotion with DMTST in 85% yield.19 The use of the
known20 perbenzylated N-phenyl triﬂuoroacetimidate donor
(NPTFA) 7a/b for the TMSOTf-catalyzed glycosylation of 4, how-
ever, resulted in decreased anomeric selectivity and a temperature
dependent outcome.21,22 Glycosylation of acceptor 4 promoted by
10% TMSOTf at 5 C in CH2Cl2 afforded the a-(1?5)-linked disac-
charide 8a as the major anomer (a/b ratio 2.4:1) accompanied by
formation of the alcohols 9a and 9b (resulting from cleavage of
the acid-labile PMB group). By lowering the temperature to
20 C and reducing the amount of promoter (5% TMSOTf) the
PMB cleavage could be largely suppressed. However, under these
conditions, the undesired 8b was formed preferentially (a/b ratio
1:1.4). The change of the solvent to CH2Cl2/Et2O (9:1) resulted in
a sluggish reaction with slightly enhanced a/b ratio (1.7:1), albeit
in poor yield. Presumably, the formation of an intermediate a-ano-
meric triﬂate at a lower temperature leads to an increased contri-
bution of an SN2-type glycosylation pathway.23 Alternatively, the
torsionally disarmed 4,6-O-benzylidene triﬂuoroacetimidate donor
10 was prepared from its hemiacetal precursor24 as a separable
anomeric mixture.25 The glycosylation of acceptor 4 with donor
10 in CH2Cl2 at 5 C provided the disaccharide 11 in 80% yield
as the a-anomer only, irrespective of the anomeric conﬁguration
of the donor (Scheme 2). Due to milder reaction conditions (lower
temperature and promoter concentration) PMB cleavage could be
completely suppressed without affecting the stereochemical out-
come. The PMB group of the a-linked disaccharide derivative 8a
was selectively removed by treatment with triﬂuoroacetic acid
(TFA) affording 9a, followed by cleavage of the silyl ether group
in order to generate the triol derivative 12. Treatment of 9a with
tetrabutylammonium ﬂuoride (TBAF) produced compound 12 in
near quantitative yield, which was then fully deprotected by cata-
lytic hydrogenation followed by alkaline hydrolysis of the methyl
ester group to furnish disaccharide 13 as sodium salt in 90% yield.
Global deprotection of the benzylidene protected disaccharide 11
provided disaccharide 13 in an excellent overall yield of 65% (based
on acceptor 4). TFA-treatment of 11 simultaneously cleaved the
benzylidene and the PMB group, respectively, to give triol 14 in
88% yield, followed by TIPDS removal and ensuing full deprotec-
tion of the resulting derivative 15 to give disaccharide 13.
In addition, the side-chain shortened analog was prepared by
oxidative cleavage of the exocyclic diol of 12with sodiummetaper-
iodate generating the heptulosonic glycoside 16. The intermediate
aldehyde formed upon oxidation could be analyzed by NMR, but
proved to be rather labile upon attempted puriﬁcation on silica
gel. The ensuing borohydride reduction was accompanied by con-
comitant ester reduction. The reaction was therefore not allowed
to run until completion, but was stopped when ester reduction4
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Scheme 2. Reagents and conditions: (a) TMSOTf, CH2Cl2, molecular sieves 4 Å, 5 C, 34% for 8a, 14% for 8b, 15% for 9a, 7% for 9b, 80% for 11; (b) 99% TFA, CH2Cl2, 0 C, 83% for
9a, 88% for 14; (c) TBAF, THF, rt, 98% for 12, 97% for 15; (d) H2 (1 atm), 10% Pd–C, MeOH, then 0.01 M aq NaOH, rt, 90% for 12?13, 95% for 15?13, 79% for 16?17; (e) NaIO4–
SiO2, CH2Cl2, 10 C, then NaBH4, MeOH, 0 C, 34%.
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afforded disaccharide 17 in 79% yield.
2.2. Preparation of the disaccharides a-Glc6P-(1?5)-a-Kdo/Kdh
Selective cleavage of the PMB-group of the benzylidene-
protected disaccharide derivative 11 via DDQ-promoted oxidation
afforded the glycosyl acceptor 18 (suitable for attachment of the
lateral Kdo unit) in 83% yield (Scheme 3). The orthogonal protect-
ing group pattern also allows for the selective introduction of the
6-phosphoester group as well as for additional glucosyl extension
at position 4 of the glucosyl unit upon reductive opening of the
benzylidene group (cf. Fig. 1). Reductive opening of the benzyli-
dene toward the 6-OH derivative 19, however, met with difﬁculties
when applying various combinations of Lewis acids and hydride
sources (CoCl2/BH3.THF, TMSCl/NaCNBH3, TMSOTf/BH3, Bu2BOTf/
BH3THF). Lack of reactivity, loss of the PMB group or cleavage of
the benzylidene group with formation of additional by-products
were observed under these conditions. A modest conversion of
compound 11 into the 4-O-benzyl ether 19 could eventually be
accomplished in the presence of PhBCl2/Et3SiH in 43% yield. Thus,
it was envisaged to introduce the 6-O-phosphate group at the
4,6-diol intermediate, with the additional option to utilize the
remaining 4-hydroxyl group as an acceptor site for future
extension by glucosyl residues. Hence, the benzylidene group of
11 was selectively removed—without cleavage of the PMBgroup—using p-toluenesulfonic acid in dry MeOH to afford the diol
20 in 91% yield. Short reaction times at 40 C gave better and repro-
ducible yields compared to prolonged reaction times at ambient
temperature. Phosphorylation of the diol 20 was ﬁrst approached
using the phosphoramidite chemistry. Thus, treatment of 20
with dibenzyl N,N-diisopropylphosphoramidite/1H-tetrazole in
the presence of ground molecular sieves (4 Å) in CH2Cl2 followed
by oxidation with mCPBA gave the 6-O-phosphotriester derivative
21 in 67% yield and the corresponding 4-O-regioisomer 22 (10%).
The phosphoramidite protocol also proved to be appropriate for
the phosphorylation of the triol 14 and furnished the 6-O-phospho-
triester derivative 25 in 63% yield. The assignment of the phos-
phate substitution at O-6 was based on the downﬁeld shift of the
1H NMR signals of the H-6 protons and the 13C–31P coupling inter-
action leading to splitting of 13C NMR signals of C-6 and C-5,
respectively. To increase the selectivity in the phosphorylation
step, a more reactive phosphoryl halide was used at a low temper-
ature. Indeed, reaction of the diol 20 with diphenyl phosphoryl
chloride at 0 C in the presence of 4-N,N-dimethylaminopyridine
afforded the corresponding 6-O-phosphotriester derivative 23 in
96% yield.
TFA-treatment of the dibenzylphosphate derivative 21 proved
to be selective for the removal of the PMB group and gave the diol
derivative 25 in 88% yield. Subsequent reaction of 25 with TBAF
afforded the tetraol derivative 26 (92%), which was subjected to
hydrogenation on 10% Pd–C followed by alkaline hydrolysis to
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Scheme 3. Reagents and conditions: (a) DDQ, CH2Cl2/MeOH (3:1), rt, 83%; (b) PhBCl2, Et3SiH, CH2Cl2, 70 C, 43%; (c) pTosOH, MeOH, 40 C, 91%; (d) (BnO)2PN(iPr)2, 1H-
tetrazole, CH2Cl2, 5 C/0 C, molecular sieves 4 Å, then mCPBA, 67% for 21, 10% for 22, 63% for 25; (e) (PhO)2P(@O)Cl, DMAP, CH2Cl2, molecular sieves 4 Å, 0 C, 96%; (f) Ac2O,
pyr., DMAP, 0 C, 96%; (g) TFA, CH2Cl2, 0 C, 88%; (h) 1 M TBAF, THF, rt, 92%; (i) H2 (1 atm), 10% Pd–C, MeOH, then 0.01 M aq NaOH, rt, 98%.
B. Pokorny et al. / Carbohydrate Research 391 (2014) 66–81 69furnish the target disaccharide phosphate 27 as sodium salt in 98%
yield. Deprotection of the silyl group of diphenylphosphate 23,
however, required a modiﬁed protocol, since treatment with TBAF
resulted in ﬂuoride-induced nucleophilic displacement of the
phenoxy groups on the phosphoester.26 The 4-OH group of 23
was thus acetylated to give compound 24 in order to prevent intra-
molecular phosphate migration or cyclization, respectively. The
silyl ether groups of 24 were then removed by the action of
triethylamine trihydrogen ﬂuoride (TREAT), which afforded 28 in
82% yield with only minor (10%) phosphate cleavage (Scheme 4).
Compound 28 was used for the preparation of the side-
chain-shortened analog 29 by periodate oxidation (36%) followed
by successive hydrogenolysis on Pd-C and PtO2, and saponiﬁcation
to afford the heptulosonic glycoside 30 in 52% yield. The poor yield
was due to formation of an unidentiﬁed side product, which had to
be separated on a HILIC column. Alternatively, dibenzylphosphateO
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Scheme 4. Reagents and conditions: (a) TREAT, CH2Cl2, rt, 82%; (b) NaIO4–SiO2, CH2Cl2,
MeOH, then H2 (1 atm), PtO2, MeOH, then 0.01 M aq NaOH, rt, 52%; (d) H2 (1 atm), 10%26 was subjected to the oxidative degradation protocol affording
31 (47%), which reacted cleanly to target compound 30 upon
hydrogenolysis with Pd–C and subsequent saponiﬁcation.
2.3. Preparation of the disaccharide a-Glc-(1?5)-a-Ko
The previously reported intermediate 32 was employed for the
preparation of a suitably protected methyl glycoside of D-glycero-
a-D-talo-oct-2-ulopyranosylonic acid (Ko).27 The epimeric 3-
O-acetate 32 was subjected to base-induced anomeric methylation
followed by de-O-acetylation to produce 33. Ensuing Dess–Martin
periodinane oxidation and reduction with ammonia–borane com-
plex gave the alcohol 34 in 65% overall yield (Scheme 5). Reaction
of 34 with benzyl bromide/NaH in DMF afforded the 3-O-benzyl
derivative 35 in 94% yield. The reaction had to be performed in
high dilution at 0 C in order to prevent formation of theO
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dene ketal was selectively cleaved by the action of p-toluenesul-
fonic acid in wet acetone under equilibrating conditions.
The use of a deﬁned amount of water was critical in order to
prevent additional loss of the 7,8-O-acetonide. This way diol 36
was obtained in 71% yield ready for further processing into suitable
glycosyl acceptor derivatives. Similar to the corresponding Kdo
acceptor 4, the 4-O-PMB group was installed via the respective
stannylidene acetal intermediate and ensuing treatment with
PMBCl/Bu4NI/DMF in toluene affording the orthogonally protected
acceptor 37 in 81% yield. Coupling of 37 with the benzylidene-pro-
tected NPTFA donor 10 promoted by TMSOTf in CH2Cl2 at 5 C
afforded the a-linked disaccharide 38 in 42% yield. The reduced
yield of the coupling step was due to the concomitant cleavage
of the acetonide during the glycosylation reaction. Deprotection
of 38 was achieved by treatment with p-toluenesulfonic acid
hydrate in methanol for 24 h which furnished the tetraol 39 in
70% yield. Hydrogenation of 39 with 10% Pd–C in methanol and
ﬁnal puriﬁcation on Bio-Gel PD10 afforded the glucosyl-Ko disac-
charide 40 as sodium salt in 92% yield. 13C NMR data of the depro-
tected target disaccharides 13, 17, 27, 30, and 40 were fully
assigned and conﬁrmed the respective structures (Table 1).Table 1
13C NMR chemical shifts (d) of disaccharide derivatives 13, 17, 27, 30, and 40
Atom position Compound
13 17
OCH3 51.42 51.31
Kdo/Kdh/Ko
1 176.03 175.93
2 101.29 100.98
3 35.47 35.36
4 66.60 66.45
5 75.95 76.73
6 72.35 73.90
7 69.24 61.67
8 63.94 —
Glc
1 100.71 100.67
2 72.80 72.74
3 73.70 73.60
4 70.05 70.03
5 72.51 72.45
6 60.77 60.732.4. Conclusions and outlook
A benzylidene-protected glucosyl NPTFA donor proved as an
efﬁcient and a-selective glycosyl donor for the glycosylation of
OH-5 of orthogonally protected Kdo and Ko glycosides and allowed
for the regioselective introduction of the 6-O-phosphoryl group.
Oxidative cleavage of the exocyclic side chain of Kdo provided
the Kdh containing fragments. Global deprotection gave the disac-
charide ligands related to the inner core region of Acinetobacter LPS
which are suited to perform various binding assays to elucidate
structural details of the interaction with MBL which are serum
components and important in innate ﬁrst-line immune reactions
such as complement activation. The synthesis of larger fragments
is currently in progress.3. Experimental
3.1. General
All purchased chemicals were used without further puriﬁca-
tion unless stated otherwise. Solvents were dried over activated27 30 40
51.42 51.31 51.64
176.06 175.95 174.16
101.30 100.99 103.26
35.22 35.16 72.76
66.42 66.31 66.95
75.48 76.46 77.19
72.35 73.95 71.75
69.01 61.63 68.96
64.07 — 63.87
100.61 100.60 100.98
72.99 72.79 72.49
73.23 73.30 73.88
69.50 69.61 69.86
72.25 71.84 72.82
JC,P 7.5 Hz JC,P 7.7 Hz
62.93 63.73 60.77
JC,P 4.1 Hz JC,P 4.5 Hz
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sieves. THF was distilled on 4 Å molecular sieves shortly before
use. Dry MeOH (secco solv) was purchased from Merck. Cation
exchange resin DOWEX 50 H+ was regenerated by consecutive
washing with HCl (3 M), water, and dry MeOH. Aqueous solu-
tions of salts were saturated unless stated otherwise. Concentra-
tion of organic solutions was performed under reduced pressure
<40 C. Optical rotations were measured with a Perkin–Elmer
243 B polarimeter. ½a20D values are given in units of 101
deg cm2 g1. Thin layer chromatography was performed on
Merck precoated plates: generally on 5  10 cm, layer thickness
0.25 mm, silica gel 60F254; alternatively on HPTLC plates with
2.5 cm concentration zone (Merck). Spots were detected by dip-
ping reagent (anisaldehyde–H2SO4). For column chromatography
silica gel (0.040–0.063 mm) was used. HP-column chromatogra-
phy was performed on pre-packed columns (YMC-Pack SIL-06,
0.005 mm, 250  10 mm and 250  20 mm). Size exclusion
chromatography was performed on Bio-Gel P-2 Gel extra ﬁne
<45 lm (wet) (Bio-Rad, 45–90 lm) or on pre-packed PD-10
columns (GE Healthcare, Sephadex™ G-25 M). NMR spectra were
recorded with a Bruker Avance III 600 instrument (600.22 MHz
for 1H, 150.93 MHz for 13C and 242.97 MHz for 31P) using
standard Bruker NMR software. 1H spectra were referenced to
7.26 (CDCl3), 5.32 (CD2Cl2), 3.31 (MeOD), and 0.00 (D2O, external
calibration to 2,2-dimethyl-2-silapentane-5-sulfonic acid) ppm
unless stated otherwise. 13C spectra were referenced to 77.00
(CDCl3), 53.84 (CD2Cl2), 49.00 (MeOD), and 67.40 (D2O, external
calibration to 1,4-dioxane) ppm. 31P spectra in D2O were refer-
enced to external ortho-phosphoric acid (0.00 ppm). ESI-MS data
were obtained on a Waters Micromass Q-TOF Ultima Global
instrument.
3.2. Methyl [methyl 3-deoxy-7,8-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-
ulopyranosid]onate (3)
A cooled mixture of 1H-imidazole (0.22 g, 3.228 mmol) and
TIPDSCl2 (0.46 mL, 1.412 mmol) in dry DMF (7.4 mL) was added
dropwise to a solution of 2 (0.36 g, 1.345 mmol) in dry DMF
(8.6 mL) at 40 C. After 2 h at 40 C another portion of
1H-imidazole (22 mg, 0.323 mmol) and TIPDSCl2 (46 lL,
0.141 mmol) in dry DMF (0.74 mL) was slowly added and after
30 min excessive reagent was scavenged by addition of dry
MeOH (2 mL). The mixture was allowed to warm up to ambient
temperature, solid NaHCO3 (0.4 g) was added, and the suspen-
sion was concentrated. The residue was partitioned between
EtOAc and aq NaHCO3, the aqueous phase was extracted with
EtOAc (2 10mL) and the combined organic layers were dried
over MgSO4, ﬁltered, and concentrated. The residual oil was
puriﬁed by column chromatography (toluene/EtOAc 4:1? 1:1)
affording 3 (0.46 g, 68%) as a colorless amorphous solid: ½a20D
+36.4 (c 0.85, CHCl3); Rf 0.38 (toluene/EtOAc 1:1); 1H NMR (CDCl3):
d 4.30–4.26 (m, 1H, H-7), 4.18 (dd, 1H, J8a,8b 12.1, J8a,7 1.7 Hz,
H-8a), 4.06–4.04 (m, 1H, H-5), 4.03–3.98 (m, 1H, H-4), 3.84 (dd,
1H, J8b,7 7.0 Hz, H-8b), 3.78 (s, 3H, CO2CH3), 3.50 (dd, J6,7 8.0, J6,5
1.0 Hz, H-6), 3.22 (s, 3 H, OCH3), 2.15 (dd, 1H, J3eq,3ax 13.0, J3eq,4
5.1 Hz, H-3eq), 1.86 (dd, 1H, J3ax,4 11.5 Hz, H-3ax), 1.12–0.93
(m, 28 H, TIPDS); 13C NMR (CDCl3): d 168.53 (s, C-1), 99.36
(s, C-2), 74.08 (d, C-7), 71.35 (d, C-6), 66.81 (t, C-8), 66.67 (d,
C-5), 66.17 (d, C-4), 52.52 (q, CO2CH3), 51.17 (q, OCH3), 35.10
(t, C-3), 17.40, 17.35, 17.33, 17.23, 17.21 [q, 8C, Si-CH-(CH3)2],
13.31, 12.77, 12.48 [d, 4C, Si-CH-(CH3)2]; ESI-TOF HRMS:
m/z = 531.2409; calcd for C22H44O9Si2Na+: 531.2416.3.3. Methyl [methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-
(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-
ulopyranosid]onate (4)
A mixture of 3 (91 mg, 0.179 mmol) and dibutyltin oxide
(49 mg, 0.197 mmol) in dry toluene (4.0 mL) was heated to reﬂux
on a Dean–Stark apparatus for 2 h. To the cooled solution dry
DMF (166 lL, 2.146 mmol), 4-methoxybenzyl chloride (73 lL,
0.537 mmol) and tetrabutylammonium iodide (73 mg,
0.197 mmol) were added successively. After 16 h at 60 C the solu-
tion was allowed to cool to ambient temperature. The solution was
diluted with EtOAc and consecutively washed with HCl (1 M), aq
NaHCO3, aq Na2S2O3 (50 g/L) and brine. The organic phase was
dried (MgSO4), ﬁltered, and concentrated. The residual oil was
taken up in dry MeOH (4.0 mL) and treated with 0.1 M NaOMe in
dry MeOH (0.179 mmol, 1.8 mL) at 0 C. After 1 h at ambient tem-
perature the solution was made neutral by adding DOWEX 50 H+
resin, the suspension was ﬁltered, and the ﬁltrate was concen-
trated. Column chromatography of the residue (toluene/EtOAc
19:1? 9:1) provided 4 (79 mg, 70%) as a colorless oil: ½a20D +24.5
(c 1.07, CHCl3); Rf 0.66 (toluene/EtOAc 3:1); 1H NMR (CDCl3): d
7.27–7.24 (m, 2H, Ar), 6.89–6.86 (m, 2H, Ar), 4.56 (d, 1H, J
11.5 Hz, CHHPh), 4.50 (d, 1H, J 11.4 Hz, CHHPh), 4.36–4.32 (m,
1H, H-7), 4.25 (dd, 1H, J8a,8b 11.9, J8a,7 1.6 Hz, H-8a), 4.14–4.12
(m, 1H, H-5), 3.84 (ddd, 1H, J4,3ax 11.5, J4,3eq 5.2, J4,5 2.9, H-4),
3.80–3.75 (m, 7H, H-8b, PhOCH3, CO2CH3), 3.38 (dd, 1H, J6,7 8.6,
J6,5 1.0 Hz, H-6), 3.20 (s, 3H, OCH3), 2.21 (bs, 1H, OH), 2.18 (dd,
1H, J3eq,3ax 12.8, H-3eq), 2.01 (dd, 1H, H-3ax), 1.18–0.91 (m, 28H,
TIPDS); 13C NMR (CDCl3): d 168.60 (s, C@O), 159.38, 130.03 (s,
2C, Ar), 129.28, 113.96 (d, 4C, Ar), 99.36 (s, C-2), 72.97 (d, 2C, C-
4, C-7), 71.88 (d, C-6), 69.99 (t, CH2Ph), 67.16 (t, C-8), 63.77 (d,
C-5), 55.26 (q, PhOCH3), 52.50 (q, CO2CH3), 50.99 (q, OCH3), 32.09
(t, C-3), 17.47, 17.41, 17.37, 17.27 [q, 8C, Si-CH-(CH3)2], 13.29,
12.82, 12.54, 12.49 [d, 4C, Si-CH-(CH3)2]; ESI-TOF HRMS: m/
z = 651.2995; calcd for C30H52O10Si2Na+: 651.2991.
Data for 5: colorless oil; ½a20D +18.2 (c 0.72, CHCl3), Rf 0.76 (tol-
uene/EtOAc 3:1); 1H NMR (CDCl3): d 7.32–7.29 (m, 2H, Ar), 7.26–
7.22 (m, 2H, Ar), 6.89–6.85 (m, 4H, Ar), 5.15 (s, 2H, CH2Ph), 4.53
(d, 1H, J 11.6 Hz, CHHPh), 4.49 (d, 1H, J 11.4 Hz, CHHPh), 4.33
(ddd, 1H, J7,6 8.6, J7,8b 7.2, J7,8a 1.5 Hz, H-7), 4.24 (dd, 1H, J8a,8b
11.8 Hz, H-8a), 4.13–4.11 (m, 1H, H-5), 3.84–3.79 (m, 7H, H-4,
2  PhOCH3), 3.76 (dd, 1H, H-8b), 3.37 (d, 1H, H-6), 3.13 (s, 3H,
OCH3), 2.21 (d, 1H, JOH,5 2.6 Hz, OH), 2.15 (dd, 1H, J3eq,3ax 12.9,
J3eq,4 4.9 Hz, H-3eq), 1.97 (dd, 1H, J3ax,4 11.7 Hz, H-3ax), 1.10–0.90
(m, 28H, TIPDS); 13C NMR (CDCl3): d 167.77 (s, C@O), 159.74,
159.37 (s, 2C, Ar), 130.26 (d, 2C, Ar), 130.03 (s, Ar), 129.29 (d, 2C,
Ar), 127.57 (s, Ar), 113.94 (d, 4C, Ar), 99.18 (s, C-2), 73.06 (d, 2C,
C-4, C-7), 71.84 (d, C-6), 69.98 (t, CH2Ph), 67.10 (t, C-8), 66.98 (t,
CH2Ph), 63.75 (d, C-5), 55.26 (q, 2C, 2  PhOCH3), 50.94 (q,
OCH3), 31.99 (t, C-3), 17.47, 17.40, 17.38, 17.27 [q, 8C, Si-CH-
(CH3)2], 13.29, 12.81, 12.54, 12.51 [d, 4C, Si-CH-(CH3)2]; ESI-TOF
HRMS: m/z = 757.3414; calcd for C37H58O11Si2Na+: 757.3410.
Data for 6: colorless amorphous solid; ½a20D 13.8 (c 0.82,
CHCl3); Rf 0.59 (toluene/EtOAc 9:1); 1H NMR (CDCl3): d 7.26–7.23
(m, 2H, Ar), 6.89–6.86 (m, 2H, Ar), 5.00–4.99 (m, 1H, H-5), 4.54
(d, 1H, J 11.9 Hz, CHHPh), 4.49 (d, 1H, J 11.8 Hz, CHHPh), 4.16
(dd, 1H, J8a,8b 12.1, J8a,7 1.7 Hz, H-8a), 3.93 (ddd, 1H, J7,6 9.5, J7,8b
7.6 Hz, H-7), 3.89 (app. td, 1H, J4,3ax 8.8, J4,3eq = J4,5 2.2 Hz, H-4),
3.80 (s, 3H, PhOCH3), 3.69 (dd, 1H, H-8b), 3.58 (s, 3H, OCH3), 3.57
(d, 1H, H-6), 2.50 (dd, 1H, J3ax,3eq 14.7 Hz, H-3ax), 2.00–1.97 (m,
1H, H-3eq), 1.12–0.91 (m, 28H, TIPDS); 13C NMR (CDCl3): d
168.24 (s, C@O), 159.54 (s, Ar), 129.36 (d, 2C, Ar), 128.92 (s, Ar),
114.03 (d, 2C, Ar), 94.91 (s, C-2), 73.37 (d, C-6), 72.71, 72.68 (d,
2C, C-5, C-7), 71.93 (d, C-4), 70.05 (t, CH2Ph), 66.64 (t, C-8), 55.25
(q, PhOCH3), 52.71 (q, OCH3), 38.72 (t, C-3), 17.40, 17.35, 17.32,
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[d, 4C, Si-CH-(CH3)2].
3.4. 2,3,4,6-Tetra-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
[methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-(1,1,3,3-tetra
isopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyranosid]
onate (8a), 2,3,4,6-tetra-O-benzyl-b-D-glucopyranosyl-(1?5)-
methyl [methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-(1,1,3,
3-tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyr
anosid]onate (8b), 2,3,4,6-tetra-O-benzyl-a-D-glucopyranosyl-
(1?5)-methyl [methyl 3-deoxy-7,8-O-(1,1,3,3-tetraisopropyl
disiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyranosid]onate (9a),
and 2,3,4,6-tetra-O-benzyl-b-D-glucopyranosyl-(1?5)-methyl
[methyl 3-deoxy-7,8-O-(1,1,3,3-tetraisopropyl disiloxane-1,3-
diyl)-a-D-manno-oct-2-ulopyranosid] onate (9b)
A solution of glycosyl acceptor 4 (50 mg, 0.080 mmol) in dry
CH2Cl2 (0.6 mL) containing 4 Å molecular sieves (75 mg) was stir-
red for 20 min followed by addition of glycosyl donor 722 (85 mg,
0.120 mmol) in dry CH2Cl2 (0.6 mL) under Ar. TMSOTf (1.4 lL,
0.008 mmol) in dry CH2Cl2 (50 lL) was added dropwise to the cold
(5 C) mixture and after 5 min the reaction was quenched by add-
ing a solution of Et3N (23 lL, 0.160 mmol) in dry CH2Cl2 (0.3 mL).
Filtration of the suspension over Celite, concentration of the ﬁl-
trate, and puriﬁcation of the residue by HP-column chromatogra-
phy (n-hexane/EtOAc 9:1? 2:1) provided target compound 8a
(31 mg, 34%) together with 8b (13 mg, 14%) and disaccharide alco-
hols 9a (14 mg, 15%) and 9b (6 mg, 7%) as colorless syrups.
Data for 8a: ½a20D +68.4 (c 0.53, CHCl3); Rf 0.62 (n-hexane/EtOAc
3:1); 1H NMR (CDCl3): d 7.36–7.20 (m, 20H, Ar), 7.10–7.07 (m, 2H,
Ar), 6.85–6.81 (m, 2H, Ar), 5.28 (d, 1H, J10 ,20 3.7 Hz, H-10), 4.94 (d,
1H, J 12.0 Hz, CHHPh), 4.86 (d, 1H, J 11.7 Hz, CHHPh), 4.83 (d, 1H,
J 11.1 Hz, CHHPh), 4.75 (d, 1H, J 10.7 Hz, CHHPh), 4.68 (d, 1H, J
12.0 Hz, CHHPh), 4.54 (d, 1H, J 11.5 Hz, CHHPh), 4.51 (d, 1H, J
12.3 Hz, CHHPh), 4.50–4.45 (m, 2H, H-7, CHHPh), 4.41 (d, 1H, J
11.0 Hz, CHHPh), 4.27 (d, 1H, J5,4 2.2 Hz, H-5), 4.24–4.19 (m, 2H,
H-50, CHHPh), 4.06 (app. t, 1H, J30 ,20 = J30 ,40 9.5 Hz, H-30), 4.01 (dd,
1H, J8a,8b 13.1, J8a,7 1.9 Hz, H-8a), 3.86–3.80 (m, 4H, H-4, CO2CH3),
3.79 (s, 3H, PhOCH3), 3.72 (app. t, 1H, J40 ,50 9.4 Hz, H-40), 3.64–
3.60 (m, 3H, H-20, H-6, H-8b), 3.40 (dd, 1H, J60a,60b 10.7, J60a,50
2.1 Hz, H-60a), 3.29 (s, 3H, OCH3), 3.12 (dd, 1H, J60b,50 1.9 Hz, H-
60b), 2.21 (dd, 1H, J3eq,3ax 12.5, J3eq,4 4.4 Hz, H-3eq), 2.16 (app. t,
1H, J3ax,4 12.2 Hz, H-3ax), 1.06–0.87 (m, 28H, TIPDS); 13C NMR
(CDCl3): d 168.80 (s, C@O), 159.07, 138.86, 138.78, 138.57,
138.11, 130.52 (s, 6C, Ar), 129.01, 128.25, 128.23, 128.21, 128.09,
127.98, 127.85, 127.82, 127.50, 127.48, 127.36, 127.00, 126.77,
113.70 (d, 24C, Ar), 99.13 (s, C-2), 98.66 (d, C-10), 81.82 (d, C-30),
80.19 (d, C-20), 77.95 (d, C-40), 75.10 (t, CH2Ph), 74.78 (t, CH2Ph),
73.62 (d, C-4), 73.29 (t, CH2Ph), 72.53 (t, CH2Ph), 71.82 (d, C-5),
71.75 (d, C-7), 71.39 (d, C-6), 70.23 (d, C-50), 69.94 (t, CH2Ph),
67.79 (t, C-60), 63.00 (t, C-8), 55.22 (q, PhOCH3), 52.34 (q, CO2CH3),
51.12 (q, OCH3), 33.21 (t, C-3), 17.60, 17.54, 17.50, 17.49, 17.29,
17.17, 17.09 [q, 8C, Si-CH-(CH3)2], 14.18, 13.55, 12.99, 12.75 [d,
4C, Si-CH-(CH3)2]; ESI-TOF HRMS: m/z = 1168.5848; calcd for C64-
H86O15Si2NH4+: 1168.5844.
Data for 8b: ½a20D +14.4 (c 0.94, CHCl3); Rf 0.60 (n-hexane/EtOAc
3:1); 1H NMR (CDCl3): d 7.37–7.34 (m, 2H, Ar), 7.29–7.22 (m, 16H,
Ar), 7.18–7.13 (m, 4H, Ar), 6.83–6.80 (m, 2H, Ar), 5.31 (d, 1H, J10 ,20
7.8 Hz, H-10), 5.08 (d, 1H, J 11.6 Hz, CHHPh), 4.89 (d, 1H, J
10.9 Hz, CHHPh), 4.81 (d, 1H, J 11.0 Hz, CHHPh), 4.78–4.76 (m,
1H, H-5), 4.74–4.71 (m, 2H, 2  CHHPh), 4.62 (d, 1H, J 11.8 Hz,
CHHPh), 4.52–4.45 (m, 4H, 1  CHHPh, 3  CHHPh), 4.35–4.31
(m, 1H, H-7), 4.27 (dd, 1H, J8a,8b 12.0, J8a,7 2.0 Hz, H-8a), 3.94
(ddd, 1H, J4,3ax 11.7, J4,3eq 4.6, J4,5 1.8 Hz, H-4), 3.81 (dd, 1H, J8b,7
6.4 Hz, H-8b), 3.78 (s, 3H, PhOCH3), 3.73–3.69 (m, 1H, H-60a),
3.65–3.55 (m, 2H, H-30, H-60b), 3.49 (s, 3H, CO2CH3), 3.46–3.39(m, 3H, H-40, H-50, H-6), 3.34 (dd, 1H, J20 ,30 9.1 Hz, H-20), 3.20 (s,
3H, OCH3), 2.26 (app. t, 1H, J3ax,3eq 12.7 Hz, H-3ax), 2.20 (dd, 1H,
H-3eq), 1.11–0.87 (m, 28H, TIPDS); 13C NMR (CDCl3): d 168.52 (s,
C@O), 159.00, 138.95, 138.67, 138.22, 138.19, 130.32 (s, 6C, Ar),
128.66, 128.35, 128.29, 128.25, 128.15, 128.01, 127.96, 127.89,
127.68, 127.56, 127.51, 127.45, 127.19, 113.79 (d, 24C, Ar),
100.49 (d, C-10), 99.36 (s, C-2), 84.73 (d, C-30), 82.31 (d, C-20),
78.36 (d, C-40), 75.81 (d, C-4), 75.75 (t, CH2Ph), 74.94 (t, CH2Ph),
74.57 (d, C-6), 74.09 (t, CH2Ph), 73.28 (d, C-50), 73.24 (t, CH2Ph),
72.69 (d, C-7), 69.86, 69.83 (t, 2C, CH2Ph, C60), 66.57 (t, C-8),
64.98 (d, C-5), 55.24 (q, PhOCH3), 52.19 (q, CO2CH3), 50.94 (q,
OCH3), 33.30 (t, C-3), 17.81, 17.79, 17.57, 17.48, 17.42, 17.34,
17.28 [q, 8C, Si-CH-(CH3)2], 13.38, 12.79, 12.74 [d, 4C, Si-CH-
(CH3)2]; ESI-TOF HRMS: m/z = 1168.5854; calcd for C64H86O15Si2
NH4+: 1168.5844.
Data for 9a: ½a20D +34.3 (c 0.64, CHCl3); Rf 0.39 (n-hexane/EtOAc
3:1); 1H NMR (CDCl3): d 7.33–7.24 (m, 18H, Ar), 7.13–7.10 (m, 2H,
Ar), 5.04 (d, 1H, J10 ,20 3.4 Hz, H-10), 4.93 (d, 1H, J 11.0 Hz, CHHPh),
4.82 (d, 1H, J 11.0 Hz, CHHPh), 4.79 (d, 1H, J 10.7 Hz, CHHPh),
4.75 (s, 2H, CH2Ph), 4.54 (d, 1H, J 12.2 Hz, CHHPh), 4.52 (m, 1H,
H-7), 4.45 (d, 1H, J 12.2 Hz, CHHPh), 4.44 (d, 1H, J 10.5 Hz, CHHPh),
4.16 (dd, 1H, J8a,8b 12.9, J8a,7 2.9 Hz, H-8a), 4.09–3.99 (m, 5H, H-30,
H-50 , H-4, H-5, H-8b), 3.79–3.77 (m, 4H, H-6, CO2CH3), 3.61–3.56
(m, 2H, H-60a, H-60b), 3.54 (dd, 1H, J20 ,30 9.6 Hz, H-20), 3.48 (dd,
1H, J 9.9, J 8.9 Hz, H-40), 3.44 (d, 1H, JOH,4 9.6 Hz, OH), 3.31 (s, 3H,
OCH3), 2.13 (dd, 1H, J3eq,3ax 12.8, J3eq,4 4.4 Hz, H-3eq), 1.86 (app. t,
1H, J3ax,4 12.5 Hz, H-3ax), 1.06–0.82 (m, 28H, TIPDS); 13C NMR
(CDCl3): d 168.57 (s, C@O), 138.67, 138.30, 137.96, 137.69 (s, 4C,
Ar), 128.39, 128.38, 128.35, 138.33, 127.99, 127.89, 127.87,
127.80, 127.73, 127.58, 127.53, 127.45 (d, 20C, Ar), 99.46 (d, C-
10), 99.03 (s, C-2), 81.42 (d, C-30), 78.74 (d, C-20), 78.60 (d, C-5),
77.87 (d, C-40), 75.37 (t, CH2Ph), 75.08 (t, CH2Ph), 73.50 (t, CH2Ph),
73.08 (d, C-7), 72.56 (t, CH2Ph), 72.05 (d, C-6), 71.39 (d, C-50), 68.67
(t, C-60), 66.79 (d, C-4), 63.87 (t, C-8), 52.37 (q, CO2CH3), 51.19 (q,
OCH3), 36.13 (t, C-3), 17.63, 17.54, 17.53, 17.50, 17.35, 17.22,
17.14 [q, 8C, Si-CH-(CH3)2], 13.98, 13.60, 12.96, 12.77 [d, 4C,
Si-CH-(CH3)2]; ESI-TOF HRMS: m/z = 1048.5273; calcd for
C56H78O14Si2NH4+: 1048.5268.
Data for 9b: ½a20D +19.7 (c 0.85, CHCl3); Rf 0.27 (n-hexane/EtOAc
3:1); 1H NMR (CDCl3): d 7.33–7.23 (m, 18H, Ar), 7.17–7.13 (m, 2H,
Ar), 5.00 (d, 1H, J 11.0 Hz, CHHPh), 4.90 (d, 1H, J 10.9 Hz, CHHPh),
4.83 (d, 1H, J 10.7 Hz, CHHPh), 4.78 (2d, 2H, J 10.7 Hz, CHHPh,
CHHPh), 4.70 (d, 1H, J10 ,20 7.9 Hz, H-10), 4.62 (d, 1H, J 11.9 Hz,
CHHPh), 4.57 (d, 1H, J 10.7 Hz, CHHPh), 4.41 (d, 1H, J 11.9 Hz,
CHHPh), 4.38 (app. dt, 1H, J7,6 = J7,8a 8.7, J7,8b 2.5 Hz, H-7), 4.17–
4.09 (m, 3H, H-5, H-8a, H-8b), 3.90 (app. ddt, 1H, J4,3ax = J4,OH
11.6, J4,3eq 4.8, J4,5 2.6 Hz, H-4), 3.81 (dd, 1H, J60a,60b 10.9, J60a,50
3.2 Hz, H-60a), 3.80 (app. t, 1H, J40 ,30 = J40 ,50 9.4 Hz, H-40), 3.78 (s,
3H, CO2CH3), 3.72–3.68 (m, 3H, H-30, H-60b, OH), 3.63 (d, 1H, H-
6), 3.55 (dd, 1H, J20 ,30 9.1 Hz, H-20), 3.41–3.37 (m, 1H, H-50), 3.26
(s, 3H, OCH3), 1.82 (dd, 1H, J3eq,3ax 12.7 Hz, H-3eq), 1.64 (app. t,
1H, H-3ax), 1.08–0.85 (m, 28H, TIPDS); 13C NMR (CDCl3): d
168.73 (s, C@O), 138.15, 137.16 (s, 4C, Ar), 128.47, 128.44,
128.39, 128.34, 127.96, 127.94, 127.8, 127.71, 127.69, 127.67,
127.60 (d, 20C, Ar), 103.86 (d, C-10), 99.21 (s, C-2), 85.57 (d, C-30),
82.12 (d, C-20), 78.06 (d, C-40), 77.23 (d, C-5), 75.53 (t, CH2Ph),
75.50 (t, CH2Ph), 75.13 (d, C-50), 74.90 (t, CH2Ph), 73.43 (t, CH2Ph),
72.73 (d, C-7), 71.12 (d, C-6), 68.75 (t, C-60), 67.43 (d, C-4), 63.88 (t,
C-8), 52.33 (q, CO2CH3), 51.20 (q, OCH3), 35.88 (t, C-3), 17.83, 17.74,
17.54, 17.47, 17.37, 17.34, 17.21, 17.15 [q, 8C, Si-CH-(CH3)2], 13.77,
13.67, 12.95, 12.84 [d, 4C, Si-CH-(CH3)2]; ESI-TOF HRMS:
m/z = 1053.4818; calcd for C56H78O14Si2Na+: 1053.4822.
Alternatively compound 9a was obtained by acid treatment of
8a:
A solution of 8a (17.6 mg, 0.015 mmol) in CH2Cl2 (14.2 mL) was
treated with 99% TFA (3.6 mL) at 0 C for 10 min. The solution was
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chromatography of the residue (n-hexane/EtOAc 5:1) yielded 9a
(13.0 mg, 83%) as a colorless oil.
3.5. 2,3-Di-O-benzyl-4,6-O-benzylidene-a,b-D-glucopyranosyl
(N-phenyl)triﬂuoroacetimidate (10a/b)
2,3-Di-O-benzyl-4,6-O-benzylidene-a,b-D-glucopyranose28 (128mg,
0.285 mmol) was dissolved in a mixture of dry CH2Cl2 (2.0 mL) and
dry acetone (0.9 mL) followed by successive addition of K2CO3
(79 mg, 0.570 mmol) and 2,2,2-triﬂuoro-N-phenylacetimidoyl
chloride (92 lL, 0.570 mmol). The heterogenous mixture was
stirred at ambient temperature for 16 h, ﬁltered through a pad of
Celite, and rinsed with CH2Cl2. After addition of one drop of
Et3N the ﬁltrate was concentrated and the crude residue was
puriﬁed by chromatography (n-hexane/EtOAc 10:1) affording an
anomeric mixture (a/b  1:8) of 10 (169 mg, 96%).
Data for 10b: colorless amorphous solid; ½a20D +49.1 (c 2.57,
CHCl3); Rf 0.75 (n-hexane/EtOAc 4:1); 1H NMR (CD2Cl2): d 7.54–
7.46 (m, 2H, Ar), 7.42–7.27 (m, 15H, Ar), 7.17–7.13 (m, 1H, Ar),
6.88–6.75 (m, 2H, Ar), 5.83 (bs, 1H, H-1), 5.60 (s, 1H, CHPh), 4.92
(d, 1H, J 11.4 Hz, CHHPh), 4.84 (d, 1H, J 11.0 Hz, CHHPh), 4.81
(2d, 2H, J 11.1 Hz, 2  CHHPh), 4.38–4.29 (m, 1H, H-6a), 3.88–
3.65 (m, 4H, H-2, H-3, H-4, H-6b), 3.45 (bs, 1H, H-5); 13C NMR (CD2-
Cl2): d 143.78, 138.94, 138.41, 137.84 (s, 4C, Ar), 129.37, 129.20,
128.75, 128.67, 128.59, 128.49, 128.41, 128.27, 128.06, 126.49,
124.88, 119.63 (d, 20C, Ar), 101.69 (d, CHPh), 81.50, 81.13, 81.11
(d, 3C, C-2, C-3, C-4), 75.71, 75.21 (t, 2C, 2  CH2Ph), 68.91 (t,
C-6), 67.06 (d, C-5).
Data for 10a: colorless oil; ½a20D +43.0 (c 1.92, CHCl3); Rf 0.61
(n-hexane/EtOAc, 4:1); 1H NMR (CD2Cl2): d 7.53–7.49 (m, 2H, Ar),
4.42–7.27 (m, 15H, Ar), 7.15–7.11 (m, 1H, Ar), 6.80–6.74 (m, 2H,
Ar), 6.45 (bs, 1H, H-1), 5.61 (s, 1H, CHPh), 4.94 (d, J 11.4 Hz,
CHHPh), 4.85 (d, J 11.3 Hz, CHHPh), 4.84 (d, J 11.8 Hz, CHHPh),
4.76 (d, J 11.9 Hz, CHHPh), 4.36 (dd, 1H, J6a,6b 10.2, J6a,5 4.8 Hz,
H-6a), 4.09 (app. t, 1H, J3,2 = J3,4 9.5 Hz, H-3), 4.03–3.96 (m, 1H,
H-5), 3.81–3.70 (m, 3H, H-2, H-4, H-6b); 13C NMR (CD2Cl2): d
144.06, 139.23, 138.46, 137.89 (s, 4C, Ar), 129.37, 129.20, 128.83,
128.63, 128.60, 128.30, 128.27, 128.12, 127.96, 126.52, 124.69,
119.75 (d, 20C, Ar), 101.82 (d, CHPh), 81.77 (d, C-4), 79.14 (d,
C-2), 78.62 (d, C-3), 75.50, 74.29 (t, 2C, 2  CH2Ph), 69.07 (t, C-6),
65.52 (d, C-5).
3.6. 2,3-Di-O-benzyl-4,6-O-benzylidene-a-D-glucopyranosyl-
(1?5)-methyl [methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-
(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-
ulopyranosid]onate (11)
A solution of donor 10a/b (74 mg, 0.119 mmol) in dry CH2Cl2
(1.0 mL) was added to dry acceptor 4 (50 mg, 0.080 mmol) under
Ar followed by addition of 4 Å molecular sieves. After stirring for
2.5 h at ambient temperature a solution of TMSOTf (0.4 lL,
0.002 mmol) in dry CH2Cl2 (0.1 mL) was added dropwise at
5 C. The reaction was quenched after 15 min by addition of
Et3N (23 lL, 0.159 mmol) in dry CH2Cl2 (0.7 mL). The mixture
was allowed to warm to ambient temperature and was ﬁltered
through a pad of Celite. The ﬁltrate was concentrated and the res-
idue was puriﬁed by chromatography (n-hexane/EtOAc 8:1?3:1,
with 0.1% TEA) to give 11 (67 mg, 80%) as a coloress oil: ½a20D
+59.7 (c 0.53, CHCl3); Rf 0.63 (n-hexane/EtOAc 3:1), 1H NMR
(CDCl3): d 7.51–7.47 (m, 2H, Ar), 7.42–7.21 (m, 15H, Ar), 6.88–
6.84 (m, 2H, Ar), 5.51 (s, 1H, CHPh), 5.28 (d, 1H, J10 ,20 3.8 Hz,
H-10), 5.08 (d, 1H, J 11.8 Hz, CHHPh), 4.96 (d, 1H, J 11.3 Hz, CHHPh),
4.75 (d, 1H, J 11.0 Hz, CHHPh), 4.66 (d, 1H, J 11.5 Hz, CHHPh), 4.57
(s, 2H, CH2Ph), 4.42–4.39 (m, 1H, H-7), 4.35 (app. dt, 1H, J50 ,40 = J50 ,60b
9.9, J50 ,60a 5.1 Hz, H-50), 4.25 (d, 1H, J5,4 2.3 Hz, H-5), 4.19 (app. t, 1H,J30 ,20 = J30 ,40 9.5 Hz, H-30), 3.96 (dd, 1H, J8a,8b 13.2, J8a,7 1.6 Hz, H-8a),
3.89 (dd, 1H, J60a,60b 10.1 Hz, H-60a), 3.85 (ddd, 1H, J4,3ax 11.6, J4,3eq
4.7, H-4), 3.81 (s, 3H, CO2CH3), 3.77 (s, 3H, PhOCH3), 3.67 (dd, 1H,
H-20), 3.64–3.59 (m, 3H, H-40, H-6, H-8b), 3.55 (app. t, 1H, J60b,50
10.2 Hz, H-60b), 3.28 (s, 3H, OCH3), 2.23 (dd, 1H, J3eq,3ax 12.5,
H-3eq), 2.17 (app. t, 1H, H-3ax), 1.14–0.77 (m, 28H, TIPDS); 13C
NMR (CDCl3): d 168.76 (s, C@O), 159.08, 138.93, 138.78, 137.79,
130.34 (s, 5C, Ar), 129.01, 128.69, 128.23, 128.10, 128.05, 127.91,
127.43, 126.96, 126.08, 113.85 (d, 19C, Ar), 100.99 (d, CHPh),
99.24 (d, C-10), 99.16 (s, C-2), 82.96 (d, C-40), 79.28 (d, C-20),
78.04 (d, C-30), 74.70 (t, CH2Ph), 73.09 (d, C-4), 71.99 (t, CH2Ph),
71.65 (d, C-5), 71.54 (d, C-7), 71.23 (d, C-6), 70.11 (t, CH2Ph),
69.08 (t, C-60), 62.79 (t, C-8), 62.37 (d, C-50), 55.19 (q, PhOCH3),
52.34 (q, CO2CH3), 51.06 (q, OCH3), 33.20 (t, C-3), 17.55, 17.49,
17.47, 17.44, 17.27, 17.16, 17.07 [q, 8C, Si-CH-(CH3)2], 14.22,
13.44, 12.99, 12.79 [d, 4C, Si-CH-(CH3)2]; ESI-TOF HRMS:
m/z = 1076.5210; calcd for C57H78O15Si2NH4+: 1076.5218.
3.7. 2,3,4,6-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl (methyl
3-deoxy-a-D-manno-oct-2-ulopyranosid)onate (12)
Compound 9a (16.0 mg, 0.016 mmol) was dissolved in dry THF
(3.3 mL) and was treated with TBAF (1 M in THF, 23 lL,
0.023 mmol) at ambient temperature for 20 min. After addition
of dry MeOH (1.7 mL) the solvent was removed in vacuo. Puriﬁca-
tion of the residue by chromatography (toluene/EtOAc 1:1) affor-
ded 12 (12.0 mg, 98%) as a colorless oil; ½a20D +36.0 (c 0.53,
CHCl3); Rf 0.18 (toluene/EtOAc 1:1); 1H NMR (CDCl3): d 7.39–7.24
(m, 18H, Ar), 7.18–7.15 (m, 2H, Ar), 4.96 (d, 1H, J 11.1 Hz, CHHPh),
4.93 (d, 1H, J 11.1 Hz, CHHPh), 4.89 (d, 1H, J 11.6 Hz, CHHPh), 4.83
(d, 1H, J 10.7 Hz, CHHPh), 4.73 (d, 1H, J10 ,20 3.7 Hz, H-10), 4.64 (d, 1H,
J 11.8 Hz, CHHPh), 4.52 (d, 1H, J 12.3 Hz, CHHPh), 4.49 (d, 1H, J
10.7 Hz, CHHPh), 4.45 (d, 1H, J 12.1 Hz, CHHPh), 4.28 (d, 1H, J
5.6 Hz, OH), 4.07 (app. t, 1H, J30 ,20 = J30 ,40 9.5 Hz, H-30), 4.03–3.95
(m, 4H, H-50, H-4, H-5, H-7), 3.86–3.81 (m, 1H, H-8a), 3.79 (s, 3H,
CO2CH3), 3.68 (dd, 1H, J6,7 8.9, J6,5 1.6 Hz, H-6), 3.66–3.61 (m, 1H,
H-8b), 3.60 (dd, 1H, J60a,60b 10.4, J60a,50 2.2 Hz, H-60a), 3.58 (dd, 1H,
H-20), 3.55 (dd, 1H, J60b,50 5.6 Hz, H-60b), 3.54 (d, 1H, J 12.5 Hz,
OH), 3.51 (app. t, 1H, J40 ,50 9.6 Hz, H-40), 3.18 (s, 3H, OCH3), 2.16–
2.11 (m, 1H, H-3eq), 2.08–2.00 (m, 1H, OH), 1.68 (app. t, 1H,
J3ax,3eq = J3ax,4 12.3 Hz, H-3ax); 13C NMR (CDCl3): d 168.20 (s,
C@O), 138.15, 137.55, 137.48, 136.60 (s, 4C, Ar), 128.85, 128.72,
128.61, 128.54, 128.53, 128.40, 128.03, 128.01, 127.89, 127.86,
127.83 (d, 20C, Ar), 100.65 (d, C-10), 98.99 (s, C-2), 81.83 (d, C-30),
80.06 (d, C-5), 78.83 (d, C-20), 78.31 (d, C-40), 75.77 (t, CH2Ph),
75.37 (t, CH2Ph), 74.96 (t, CH2Ph), 73.51 (t, CH2Ph), 71.98 (d, C-6),
71.75 (d, C-50), 69.06 (d, C-7), 68.44 (t, C-60), 65.85 (d, C-4), 64.32
(t, C-8), 52.46 (q, CO2CH3), 51.02 (q, OCH3), 36.12 (t, C-3);
ESI-TOF HRMS: m/z = 811.3299; calcd for C44H52O13Na+: 811.3300.
3.8. a-D-Glucopyranosyl-(1?5)-sodium (methyl 3-deoxy-a-D-
manno-2-oct-2-ulopyranosid)onate (13)
Compound 12 (11.2 mg, 0.014 mmol) was dissolved in dry
MeOH (0.5 mL). The atmosphere was exchanged to argon by alter-
nating evacuation and ﬂushing with argon. Then, palladium on
active charcoal (10%, 1 mg) was added to the ﬂask followed by suc-
cessive exchange of the atmosphere to argon and hydrogen using
the same method described before. The mixture was stirred inten-
sively for 3 h, diluted with MeOH, and passed through a 0.45 lm
syringe ﬁlter. Concentration of the ﬁltrate afforded debenzylated
methyl ester which was saponiﬁed with aq NaOH (0.01 M,
2.0 mL) at ambient temperature for 1.5 h. The solution was neu-
tralized by addition of freshly regenerated DOWEX 50 H+, the
ion-exchange resin was ﬁltered off, and the ﬁltrate was lyophilized.
Puriﬁcation by SEC (Bio-Gel P2 gel, 5% aq EtOH) and freeze-drying
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phous solid; ½a20D +99.9 (c 0.56, D2O); 1H NMR (D2O): 5.11 (d, 1H,
J10 ,20 4.0 Hz, H-10), 4.12–4.03 (m, 4H, H-4, H-5, H-7, H-50), 3.89
(dd, 1H, J8a,8b 11.8, J8a,7 2.8 Hz, H-8a), 3.79–3.68 (m, 3H, H-30,
H-60a, H-60b), 3.62 (dd, 1H, J8b,7 6.1 Hz, H-8b), 3.56–3.54 (m, 1H,
H-6), 3.49 (dd, 1H, J20 ,30 10.0 Hz, H-20), 3.41 (dd, 1H, J 10.0, J
9.0 Hz, H-40), 3.11 (s, 3H, OCH3), 1.99–1.95 (m, 1H, H-3eq), 1.82
(app. t, 1H, J3ax,3eq = J3ax,4 12.5 Hz, H-3ax); 13C NMR data: see
Table 1; ESI-TOF HRMS: m/z = 413.1296; calcd for C15H25O13 :
413.1301.
3.9. 2,3-Di-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl [methyl
3-deoxy-7,8-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-a-D-
manno-oct-2-ulopyranosid]onate (14)
Compound 11 (50.0 mg, 0.047 mmol) was treated with triﬂuo-
roacetic acid (99%, 1.0 mL) in CH2Cl2 (8.0 mL) at 0 C for 10 min.
The solution was concentrated, coevaporated with toluene, and
the crude product was puriﬁed by chromatography (n-hexane/
EtOAc 3:1, then 1:2) yielding 14 (40.2 mg, 88%) as a colorless oil;
½a20D +79.6 (c 0.52, CHCl3); Rf 0.24 (n-hexane/EtOAc 1:2); 1H NMR
(CDCl3): d 7.36–7.26 (m, 10H, Ar), 5.09 (d, 1H, J10 ,20 3.4 Hz, H-10),
4.91 (d, 1H, J 11.6 Hz, CHHPh), 4.79 (d, 1H, J 12.4 Hz, CHHPh),
4.75 (d, 1H, J 12.5 Hz, CHHPh), 4.71 (d, 1H, J 11.5 Hz, CHHPh),
4.44 (app. td, 1H, J7,6 8.3, J7,8a = J7,8b 2.3 Hz, H-7), 4.14 (dd, 1H,
J8a,8b 12.8 Hz, H-8a), 4.10–4.05 (m, 2H, H-4, H-5), 4.03–3.97 (m,
2H, H-50, H-8b), 3.85 (app. t, 1H, J30 ,20 = J30 ,40 8.6 Hz, H-30), 3.81–
3.76 (m, 5H, CO2CH3, H-6, H-60a), 3.73 (dd, 1H, J60b,60a 11.7, J60b,50
5.6 Hz, H-60b), 3.53 (dd, 1H, H-20), 3.49 (app. t, 1H, J40 ,50 8.7 Hz,
H-40), 3.31 (s, 3H, OCH3), 2.17 (m, 1H, H-3eq), 1.90 (app. t, 1H,
J3ax,3eq = J3ax,4 12.2 Hz, H-3ax), 1.07–0.81 (m, 28H, TIPDS); 13C
NMR (CDCl3): d 168.62 (s, C@O), 138.38, 138.02 (s, 2C, Ar),
128.58, 128.41, 127.96, 127.91, 127.67, 127.42 (d, 10C, Ar), 99.07
(s, C-2), 98.90 (d, C-10), 80.20 (d, C-30), 78.39 (d, C-20), 77.62 (d,
C-5), 74.73 (t, CH2Ph), 73.12 (d, C-50), 72.91 (d, C-7), 72.55 (t, CH2-
Ph), 71.79 (d, C-6), 69.91 (d, C-40), 66.60 (d, C-4), 63.70 (t, C-8),
62.19 (t, C-60), 52.42 (q, CO2CH3), 51.20 (q, OCH3), 36.15 (t, C-3),
17.56, 17.52, 17.50, 17.44, 17.31, 17.20, 17.12 [q, 8C, Si-CH-
(CH3)2], 14.00, 13.57, 12.93, 12.77 [d, 4C, Si-CH-(CH3)2]; ESI-TOF
HRMS: m/z = 873.3880; calcd for C42H66O14Si2Na+: 873.3883.
3.10. 2,3-Di-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
(methyl 3-deoxy-a-D-manno-oct-2-ulopyranosid)onate (15)
TBAF (1 M in THF, 28 lL, 0.028 mmol) was added to a solution
of 14 (15.9 mg, 0.019 mmol) in dry THF (1.0 mL) at ambient
temperature and stirred for 5 min. Dry MeOH (2.0 mL) was added
followed by concentration. The residue was puriﬁed by chromatog-
raphy (EtOAc, then EtOAc/methanol 19:1) to provide 15 (11.0 mg,
97%) as a colorless oil; ½a20D +50.6 (c 0.52, CHCl3); Rf 0.22 (EtOAc);
1H NMR (CDCl3): d 7.41–7.30 (m, 10H, Ar), 4.98 (d, 1H, J 11.4 Hz,
CHHPh), 4.91 (d, 1H, J 11.6 Hz, CHHPh), 4.85 (d, 1H, J 11.4 Hz,
CHHPh), 4.77 (d, 1H, J10 ,20 3.6 Hz, H-10), 4.66 (d, 1H, J 11.5 Hz,
CHHPh), 4.20 (d, 1H, J 5.8 Hz, OH), 4.06–3.97 (m, 3H, H-4, H-5,
H-7), 3.92 (app. t, 1H, J30 ,20 = J30 ,40 9.3 Hz, H-30), 3.86–3.78 (m, 6H,
CO2CH3, H-50, H-60a, H-8a), 3.75–3.68 (m, 2H, H-60b, H-6), 3.66–
3.61 (m, 1 H, H-8b), 3.57 (app. dt, 1H, J40 ,50 9.3, J40 ,OH 3.2 Hz, H-40),
3.54 (dd, 1H, H-20), 3.44 (d, 1H, J 11.7 Hz, OH), 3.19 (s, 3H, OCH3),
2.63 (d, 1H, JOH,40 3.7 Hz, OH), 2.20 (dd, 1H, J3eq,3ax 12.6, J3eq,4
4.3 Hz, H-3eq), 2.14–2.07 (m, 2H, 2  OH), 1.73–1.65 (m, 1H,
H-3ax); 13C NMR (CDCl3): d 168.40 (s, C@O), 138.17, 136.48 (s,
2C, Ar), 128.89, 128.80, 128.73, 128.63, 128.11, 127.90 (d, 10C,
Ar), 100.72 (d, C-10), 99.04 (s, C-2), 81.33 (d, C-30), 79.78 (d, C-5),
78.97 (d, C-20), 75.60 (t, CH2Ph), 74.86 (t, CH2Ph), 73.01 (d, C-50),
71.90 (d, C-6), 70.69 (d, C-40), 69.06 (d, C-7), 65.87 (d, C-4), 64.19
(t, C-8), 62.01 (t, C-60), 52.62 (q, CO2CH3), 51.10 (q, OCH3), 36.20(t, C-3); ESI-TOF HRMS: m/z = 626.2804; calcd for C30H40O13NH4+:
626.2807.
Deprotection of 15: A solution of 15 (5.6 mg, 0.009 mmol) in dry
MeOH (1.0 mL) was hydrogenated for 4 h with 10% Pd–C (1 mg) as
described for 13. The suspension was diluted with MeOH and
passed through a 0.45 lm syringe ﬁlter. Concentration of the ﬁl-
trate afforded the debenzylated methyl ester which was treated
with 0.01 M aq NaOH (1.0 mL) at ambient temperature for 12 h.
The solution was made neutral by addition of DOWEX 50 H+ resin.
The ion-exchange resin was ﬁltered off and the ﬁltrate was lyoph-
ilized. Puriﬁcation of the residue on Bio-Gel PD10 column (H2O)
and freeze-drying of pooled fractions provided 13 (3.8 mg, 95%)
as a colorless amorphous solid.
3.11. 2,3,4,6-Tetra-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
(methyl 3-deoxy-a-D-lyxo-2-hept-2-ulopyranosid)onate (16)
A solution of 12 (32.0 mg, 0.041 mmol) in dry CH2Cl2 (3.5 mL)
was cooled to 10 C. Sodium metaperiodate on silica (15 w%,
116 mg, 0.082 mmol) was added and the suspension was stirred
for 1 h at 10 C with exclusion of light. The excess of reagent
was destroyed by addition of ethylene glycol (3 w% in water,
84 lL, 0.041 mmol). The mixture was diluted with CHCl3 and
extracted with distilled water. The aqueous phase was further
extracted with CH2Cl2 (3  5 mL) and the combined organic
extracts were dried (Na2SO4), ﬁltered, and concentrated. The crude
material was dissolved in dry MeOH (1.0 mL), cooled to 0 C, and
treated with sodium borohydride (2.5 mg, 0.065 mmol) for 1 h.
Another portion of sodium borohydride (1.0 mg, 0.026 mmol)
was added at 0 C and after 5 min the solution was diluted with
EtOAc and aq NH4Cl. The aqueous phase was extracted with EtOAc
(3  5 mL) and the combined organic layers were dried (Na2SO4).
Concentration of the solution gave a crude product which was
puriﬁed by HP-column chromatography (n-hexane/EtOAc
4:1? 3:2) to afford 16 (10.4 mg, 34%) as a colorless oil; ½a20D
+40.4 (c 0.96, CHCl3); Rf 0.54 (toluene/EtOAc 1:2); 1H NMR (CDCl3):
d 7.39–7.26 (m, 18H, Ar), 7.18–7.15 (m, 2H, Ar), 4.95–4.91 (m, 2H,
CH2Ph), 4.85 (d, 1H, J 11.8 Hz, CHHPh), 4.84 (d, 1H, J 10.6 Hz,
CHHPh), 4.74 (d, 1H, J10 ,20 3.5 Hz, H-10), 4.64 (d, 1H, J 11.9 Hz,
CHHPh), 4.52 (d, 1H, J 11.8 Hz, CHHPh), 4.49 (d, 1H, J 10.7 Hz,
CHHPh), 4.45 (d, 1H, J 12.4 Hz, CHHPh), 4.06 (app. t, 1H, J30 ,20 = J30 ,40
9.4 Hz, H-30), 4.04–3.98 (m, 2H, H-50, H-4), 3.92–3.86 (m, 2H, H-5,
H-7a), 3.86–3.83 (m, 1H, H-6), 3.82–3.78 (m, 4H, H-7b, CO2CH3),
3.60 (dd, 1H, J60a,60b 10.3, J60a,50 2.1 Hz, H-60a), 3.58–3.54 (m, 2H,
H-20, H-60b), 3.54–3.48 (m, 2H, H-40, OH), 3.21 (s, 3H, OCH3), 2.15
(dd, 1H, J3eq,3ax 12.2, J3eq,4 4.5 Hz, H-3eq), 1.71 (app. t, 1H, J3ax,4
12.5 Hz, H-3ax); 13C NMR (CDCl3): d 168.28 (s, C@O), 138.25,
137.63, 137.53, 136.83 (s, 4C, Ar), 128.82, 128.62, 128.51, 128.40,
128.02, 127.99, 127.88, 127.83, 127.80 (d, 20C, Ar), 100.47 (d, C-
10), 99.03 (s, C-2), 81.74 (d, C-30), 79.80 (d, C-5), 79.22 (d, C-20),
78.11 (d, C-40), 75.80 (t, CH2Ph), 75.36 (t, CH2Ph), 74.77 (t, CH2Ph),
73.49 (t, CH2Ph), 71.77 (d, C-50), 71.59 (d, C-6), 68.49 (t, C-60), 65.95
(d, C-4), 60.64 (t, C-7), 52.50 (q, CO2CH3), 51.01 (q, OCH3), 36.27 (t,
C-3); ESI-TOF HRMS: m/z = 781.3198; calcd for C43H50O12Na+:
781.3194.
3.12. a-D-Glucopyranosyl-(1?5)-sodium (methyl 3-deoxy-a-D-
lyxo-hept-2-ulopyranosid)onate (17)
A solution of 16 (8.0 mg, 0.011 mmol) in dry MeOH (0.5 mL)
was hydrogenated for 4 h with 10% Pd–C (1 mg) as described for
13. Another portion of catalyst (1 mg) was added and stirring
under H2 was continued for 19 h. The suspension was diluted with
MeOH and passed through a 0.45 lm syringe ﬁlter. Concentration
of the ﬁltrate afforded the debenzylated methyl ester which was
treated with 0.01 M aq NaOH (1.5 mL) at ambient temperature
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H+ resin. The ion-exchange resin was ﬁltered off and the ﬁltrate
was lyophilized. Puriﬁcation of the residue on Bio-Gel P2 (5% aq
EtOH) and freeze-drying of pooled fractions provided 17 (3.4 mg,
79%) as a colorless amorphous solid; ½a20D +170.7 (c 0.28, D2O);
1H NMR (D2O): 4.89 (d, 1H, J10 ,20 3.8 Hz, H-10), 4.10 (ddd, 1H, J3ax,4
12.3, J3eq,4 4.8, J5,4 3.0 Hz, H-4), 4.06 (ddd, 1H, J60a,50 3.5, J60b,50 2.6,
J40 ,50 10.3 Hz, H-50), 3.96 (dd, 1H, J7a,7b 11.4, J7a,6 8.2 Hz, H-7a),
3.88 (br d, 1H, H-5), 3.81 (dd, 1H, J7b,6 4.7 Hz, H-7b), 3.76-3.68
(m, 4H, H-6, H-30, H-60a, H-60b), 3.48 (dd, 1H, J20 ,30 10.0 Hz, H-20),
3.41 (app. t, 1H, J40 ,30 9.1 Hz, H-40), 3.14 (s, 3H, OCH3), 2.01–1.99
(m, 1H, H-3eq), 1.82 (app. t, 1H, J3ax,3eq 12.6 Hz, H-3ax); 13C NMR
data: see Table 1; ESI-TOF HRMS: m/z = 383.1193; calcd for
C14H23O12 : 383.1195.
3.13. 2,3-Di-O-benzyl-4,6-O-benzylidene-a-D-glucopyranosyl-
(1?5)-methyl [methyl 3-deoxy-7,8-O-(1,1,3,3-tetraisopropyl
disiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyranosid]
onate (18)
2,3-Dichloro-4,5-dicyano-p-benzoquinone (26.2 mg, 0.116mmol)
was added in four portions during 1 h to a solution of 11
(15.3 mg, 0.014 mmol) in dry CH2Cl2 (0.9 mL) and dry MeOH
(0.3 mL). After complete addition the mixture was stirred at ambi-
ent temperature for 1.5 h, diluted with CHCl3, and washed with aq
NaHCO3. The aqueous phase was extracted with CH2Cl2 (2  5 mL)
and the combined organic phases were washed with aq NaHCO3,
dried (MgSO4), ﬁltered, and concentrated. To remove aromatic
impurities the crude product was dissolved in toluene and sub-
jected to chromatography (toluene?toluene/EtOAc 9:1) to afford
18 (11.2 mg, 83%) as a colorless oil; ½a20D +52.2 (c 0.54, CHCl3); Rf
0.30 (n-hexane/EtOAc 3:1); 1H NMR (CDCl3): d 7.49–7.47 (m, 2H,
Ar), 7.39–7.24 (m, 13H, Ar), 5.54 (s, 1H, CHPh), 5.11 (d, 1H, J10 ,20
3.9 Hz, H-10), 4.93 (d, 1H, J 11.2 Hz, CHHPh), 4.90 (d, 1H, J
12.2 Hz, CHHPh), 4.79 (d, 1H, J 11.2 Hz, CHHPh), 4.75 (d, 1H, J
12.5 Hz, CHHPh), 4.47 (app. dt, 1H, J7,6 = J7,8a 8.7, J7,8b 2.1 Hz,
H-7), 4.24 (dd, 1H, J60a,60b 10.4, J60a,50 4.9 Hz, H-60a), 4.15–4.07 (m,
5H, H-30, H-50, H-4, H-5, H-8a), 3.90 (dd, 1H, J8b,8a 12.9 Hz, H-8b),
3.80 (s, 3H, CO2CH3), 3.75 (d, 1H, H-6), 3.69 (app. t, 1H, J60b,50
10.4 Hz, H-60b), 3.65 (app. t, 1H, J40 ,30 = J40 ,50 9.5 Hz, H-40), 3.62 (dd,
1H, J20 ,30 9.0 Hz, H-20), 3.32 (s, 3H, OCH3), 2.85 (bs, 1H, OH),
2.20–2.16 (m, 1H, H-3eq), 1.92 (app. t, 1H, J3ax,3eq = J3ax,4 12.2 Hz,
H-3ax), 1.05–0.81 (m, 28H, TIPDS); 13C NMR (CDCl3): d 168.53 (s,
C@O), 138.59, 138.39, 137.28 (s, 3C, Ar), 128.90, 128.27, 128.22,
127.96, 127.56, 127.46, 127.41, 125.97 (d, 15C, Ar), 101.13 (d,
CHPh), 100.05 (d, C-10), 99.07 (s, C-2), 82.09 (d, C-40), 78.26 (d,
C-20), 78.18 (d, C-30), 77.25 (d, C-5), 74.84 (t, CH2Ph), 72.57 (t,
CH2Ph), 72.32 (d, C-7), 71.49 (d, C-6), 68.75 (t, C-60), 66.50 (d,
C-4), 63.37 (d, C-50), 63.33 (t, C-8), 52.46 (q, CO2CH3), 51.22 (q,
OCH3), 36.28 (t, C-3), 17.62, 17.53, 17.52, 17.49, 17.32, 17.18,
17.11 [q, 8C, Si-CH-(CH3)2], 14.12, 13.58, 12.96, 12.81 [d, 4C,
Si-CH-(CH3)2]; ESI-TOF HRMS: m/z = 961.4190; calcd for C49H70O14
Si2Na+: 961.4196.
3.14. 2,3,4-Tri-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
[methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-
ulopyranosid]onate (19)
A suspension of compound 11 (20.0 mg, 0.019 mmol) and 4 Å
molecular sieves (70 mg) in dry CH2Cl2 (0.8 mL) was cooled to
70 C followed by consecutive addition of triethylsilane (9.8 lL,
0.061 mmol) and dichlorophenylborane (7.2 lL, 0.055 mmol).
After 1 h Et3N (44 lL) and dry MeOH (44 lL) were added to the
cold solution. The mixture was diluted with CHCl3, allowed to
warm up to ambient temperature and washed with aq NaHCO3.The aqueous layer was extracted with CH2Cl2 (3  5 mL), the com-
bined organic layers were dried (Na2SO4) and concentrated. The
residue was puriﬁed by column chromatography (n-hexane/EtOAc
9:1? 3:1) to give 19 (8.6 mg, 43%) as a colorless oil; ½a20D +87.6 (c
0.78, CHCl3); Rf 0.31 (n-hexane/EtOAc 3:1); 1H NMR (CDCl3): d
7.36–7.21 (m, 17H, Ar), 6.84–6.81 (m, 2H, Ar), 5.25 (d, 1H, J10 ,20
3.7 Hz, H-10), 4.93 (d, 1H, J 12.0 Hz, CHHPh), 4.88–4.82 (m, 3H,
CHHPh, CH2Ph), 4.68 (d, 1H, J 12.0 Hz, CHHPh), 4.63 (d, 1H, J
11.0 Hz, CHHPh), 4.51 (d, 1H, J 11.6 Hz, CHHPh), 4.49 (d, 1H, J
11.8 Hz, CHHPh), 4.40 (app. td, 1H, J7,6 9.3, J7,8a = J7,8b 1.9 Hz, H-
7), 4.23–4.21 (m, 1H, H-5), 4.20 (app. td, 1H, J50 ,40 10.1, J50 ,60a = J50 ,60b
2.8 Hz, H-50), 4.09 (app. t, 1H, J30 ,20 = J30 ,40 9.4 Hz, H-30), 4.01 (dd, 1H,
J8a,8b 13.0 Hz, H-8a), 3.83 (ddd, 1H, J4,3ax 11.8, J4,3eq 4.6, J4,5 2.4 Hz,
H-4), 3.81 (s, 3H, CO2CH3), 3.77 (s, 3H, PhOCH3), 3.67 (dd, 1H,
H-8b), 3.61 (d, 1H, H-6), 3.57–3.51 (m, 2H, H-20, H-40), 3.45–3.41
(m, 2H, H-60a, H-60b), 3.27 (s, 3H, OCH3), 2.22 (dd, 1H, J3eq,3ax
12.5, H-3eq), 2.15 (app. t, 1H, H-3ax), 1.57–1.53 (m, 1H, OH),
1.04–0.78 (m, 28H, TIPDS); 13C NMR (CDCl3): d 168.79 (s, C@O),
159.14, 138.77, 138.72, 138.42, 130.22 (s, 5C, Ar), 129.05, 128.40,
128.29, 128.14, 127.98, 127.86, 127.73, 127.44, 127.09, 126.82,
113.77 (d, 19C, Ar), 99.15 (s, C-2), 98.09 (d, C-10), 81.52 (d, C-30),
80.24 (d, C-40), 77.79 (d, C-20), 75.12 (t, CH2Ph), 74.84 (t, CH2Ph),
73.22 (d, C-4), 72.52 (t, CH2Ph), 71.86 (d, C-7), 71.57 (d, C-5),
71.37 (d, C-6), 70.73 (d, C-50), 69.81 (t, CH2Ph), 63.02 (t, C-8),
61.43 (t, C-60), 55.23 (q, PhOCH3), 52.38 (q, CO2CH3), 51.10 (q,
OCH3), 33.02 (t, C-3), 17.53, 17.50, 17.49, 17.46, 17.28, 17.17,
17.08 [q, 8C, Si-CH-(CH3)2], 14.17, 13.59, 12.98, 12.78 [d, 4C,
Si-CH-(CH3)2]; ESI-TOF HRMS: m/z = 1078.5373; calcd for C57H80
O15Si2NH4+: 1078.5374.
3.15. 2,3-Di-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
[methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,8-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-
ulopyranosid]onate (20)
A solution of 11 (59 mg, 0.056 mmol) and p-toluenesulfonic
acid monohydrate (1 mg, 0.006 mmol) in dry MeOH (2.5 mL) was
stirred at 40 C for 2 h. The solution was allowed to cool to ambient
temperature followed by treatment with solid NaHCO3 (25 mg) for
2 min. After removal of the solvent, the residue was partitioned
between EtOAc and aq NaHCO3, the aqueous layer was washed
with EtOAc (2  10 mL) and the combined organic phases were
dried (Na2SO4), ﬁltered, and concentrated. The residue was puriﬁed
by chromatography (n-hexane/EtOAc 7:3) providing 20 (49 mg,
91%) as a colorless oil; ½a20D +86.0 (c 0.44, CHCl3); Rf 0.70 (n-hex-
ane/EtOAc 1:1); 1H NMR (CDCl3): d 7.38–7.35 (m, 2H, Ar), 7.34–
7.22 (m, 10H, Ar), 6.87–6.84 (m, 2H, Ar), 5.27 (d, 1H, J10 ,20 3.4 Hz,
H-10), 4.89 (d, 1H, J 11.9 Hz, CHHPh), 4.88 (d, 1H, J 11.8 Hz, CHHPh),
4.74 (d, 1H, J 11.3 Hz, CHHPh), 4.71 (d, 1H, J 12.0 Hz, CHHPh), 4.52
(s, 2H, CH2Ph), 4.40–4.37 (m, 1H, H-7), 4.25–4.23 (m, 1H, H-5), 4.14
(app. td, 1H, J50 ,40 9.9, J50 ,60a = J50 ,60b 3.8 Hz, H-50), 4.02 (dd, 1H, J8a,8b
13.1, J8a,7 1.9 Hz, H-8a), 3.91 (app. t, 1H, J30 ,20 = J30 ,40 9.5 Hz, H-30),
3.86–3.82 (m, 4H, H-4, CO2CH3), 3.80 (s, 3H, PhOCH3), 3.69 (dd,
1H, J8b,7 2.1 Hz, H-8b), 3.63 (d, 1H, J6,7 9.6 Hz, H-6), 3.57 (app. dt,
1H, J40 ,OH 2.8 Hz, H-40), 3.53–3.45 (m, 3H, H-20, H-60a, H-60b), 3.28
(s, 3H, OCH3), 2.25–2.20 (m, 2H, H-3eq, OH), 2.15 (app. t, 1H,
J3ax,3eq = J3ax,4 12.1 Hz, H-3ax), 1.67–1.63 (m, 1H, OH), 1.05–0.79
(m, 28H, TIPDS); 13C NMR (CDCl3): d 168.84 (s, C@O), 159.20,
138.70, 138.51, 130.20 (s, 4C, Ar), 129.05, 128.50, 128.21, 127.99,
127.75, 127.22, 126.89, 113.81 (d, 14C, Ar), 99.18 (s, C-2), 98.06
(d, C-10), 80.72 (d, C-30), 79.87 (d, C-20), 74.68 (t, CH2Ph), 73.19 (d,
C-4), 72.30 (t, CH2Ph), 71.96 (d, C-7), 71.50 (d, C-5), 71.38 (d,
C-6), 70.94 (d, C-40), 70.76 (d, C-50), 69.84 (t, CH2Ph), 63.07
(t, C-8), 62.44 (t, C-60), 55.26 (q, PhOCH3), 52.40 (q, CO2CH3),
51.14 (q, OCH3), 33.11 (t, C-3), 17.51, 17.48, 17.44, 17.27, 17.17,
17.08 [q, 8C, Si-CH-(CH3)2], 14.14, 13.61, 12.97, 12.78 [d, 4C,
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O15Si2NH4+: 988.4905.
3.16. 2,3-Di-O-benzyl-6-O-(dibenzylphosphoryl)-a-D-glucopyran
osyl-(1?5)-methyl [methyl 3-deoxy-4-O-(4-methoxybenzyl)-7,
8-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-
2-ulopyranosid]onate (21) and 2,3-di-O-benzyl-4-O-(dibenzyl
phosphoryl)-a-D-glucopyranosyl-(1?5)-methyl [methyl 3-
deoxy-4-O-(4-methoxybenzyl)-7,8-O-(1,1,3,3-tetra
isopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyranosid]
onate (22)
A solution of 20 (47.0 mg, 0.048 mmol) in dry CH2Cl2 (3.0 mL)
was ﬂushed with Ar before 1H-tetrazole (6.8 mg, 0.097 mmol) and
4 Å molecular sieves (50 mg) were added. The suspension was stir-
red for30 minat ambient temperatureand cooled to5 C.Dibenzyl
N,N-diisopropylphosphoramidite (15.9 lL, 0.048 mmol) in dry
CH2Cl2 (1.0 mL) was added dropwise at5 C. After 30 min another
portion of dibenzyl N,N-diisopropylphosphoramidite (4.0 lL,
0.012 mmol) in dry CH2Cl2 (0.25 mL) was added at 5 C and after
15 min the solution was treated with m-chloroperbenzoic acid
(70 w%, 23.9 mg, 0.097 mmol) for 5 min. The reaction mixture was
partitioned between aq NaHCO3 and CH2Cl2, the aqueous phase
was extracted with CHCl3 (2  10 mL) and the combined organic
phases were dried (MgSO4), ﬁltered, and concentrated. Puriﬁcation
by HP-column chromatography (n-hexane/EtOAc 3:1? 3:2) pro-
vided 21 (39.6 mg, 67%) and 22 (5.8 mg, 10%) as colorless oils.
Data for 21: ½a20D +96.7 (c 0.32, CHCl3); Rf 0.19 (n-hexane/EtOAc
2:1, HPTLC); 1H NMR (CDCl3): d 7.37–7.19 (m, 22H, Ar), 6.84–6.81
(d, 2H, Ar), 5.21 (d, 1H, J10 ,20 3.6 Hz, H-10), 5.03–4.89 (m, 6H,
2  CHHPh, 2  POCHHPh, 2  POCHHPh), 4.80 (d, 1H, J 11.2 Hz,
CHHPh), 4.64 (d, 1H, J 11.9 Hz, CHHPh), 4.47 (d, 1H, J 11.4 Hz,
CHHPh), 4.44 (d, 1H, J 11.4 Hz, CHHPh), 4.42 (app. td, 1H, J7,6 9.8,
J7,8a = J7,8b 1.7 Hz, H-7), 4.22–4.20 (m, 1H, H-5), 4.17–4.14 (m, 1H,
H-50), 4.00–3.92 (m, 3H, H-30, H-60a, H-8a), 3.85–3.81 (m, 4H, H4,
CO2CH3), 3.70 (s, 3H, PhOCH3), 3.66–3.53 (m, 4H, H-40, H-60b,
H-6, H-8b), 3.49 (dd, 1H, J20 ,30 9.7 Hz, H-20), 3.45–3.41 (m, 1H,
OH), 3.28 (s, 3H, OCH3), 2.23 (dd, 1H, J3eq,3ax 12.5, J3eq,4 4.1 Hz,
H-3eq), 2.11 (app. t, 1H, J3ax,4 12.2 Hz, H-3ax), 1.02–0.72 (m, 28H,
TIPDS); 13C NMR (CDCl3): d 168.79 (s, C@O), 159.20, 138.95,
138.77 (s, 3C, Ar), 135.72 (s, JC,P 6.7 Hz, Ar), 135.62 (s, JC,P 7.3 Hz,
Ar), 130.14 (s, Ar), 129.22, 128.52, 128.49, 128.27, 128.07, 127.96,
127.93, 127.88, 127.44, 127.01, 126.81, 113.79 (d, 24C, Ar), 99.11
(s, C-2), 98.76 (d, C-10), 80.47 (d, C-30), 79.46 (d, C-20), 74.89 (t, CH2-
Ph), 73.32 (d, C-4), 72.22 (t, CH2Ph), 71.94 (d, C-5), 71.58 (d, C-7),
71.30 (d, C-6), 70.24 (d, JC,P 4.8 Hz, C-50), 69.96 (t, CH2Ph), 69.64
(d, C-40), 69.47 (t, JC,P 5.4 Hz, POCH2Ph), 69.32 (t, JC,P 5.8 Hz, POCH2-
Ph), 66.00 (t, JC,P 5.4 Hz, C-60), 62.83 (t, C-8), 55.14 (q, PhOCH3),
52.37 (q, CO2CH3), 51.10 (q, OCH3), 33.02 (t, C-3), 17.54, 17.48,
17.44, 17.26, 17.14, 17.06 [q, 8C, Si-CH-(CH3)2], 14.16, 13.40,
12.98, 12.74 [d, 4C, Si-CH-(CH3)2]; 31P NMR (CDCl3): d 0.81;
ESI-TOF HRMS: m/z = 1253.5072; calcd for C64H87O18PSi2Na+:
1253.5061.
Data for 22: colorless oil; ½a20D +72.4 (c 0.53, CHCl3); Rf 0.26
(n-hexane/EtOAc 2:1, HPTLC); 1H NMR (CDCl3): d 7.35–7.08 (m,
22H, Ar), 6.84–6.81 (m, 2H, Ar), 5.30 (d, 1H, J10 ,20 3.8 Hz, H-10),
5.00 (dd, 1H, J 11.8, JH,P 7.9 Hz, POCHHPh), 4.94–4.87 (m, 3H,
CHHPh, POCH2Ph), 4.84 (dd, 1H, J 11.9, JH,P 9.8 Hz, POCHHPh),
4.81 (d, 1H, J 12.2 Hz, CHHPh), 4.79 (d, 1H, J 11.9 Hz, CHHPh),
4.65 (d, 1H, J 11.9 Hz, CHHPh), 4.54 (d, 1H, J 11.9 Hz, CHHPh),
4.50 (d, 1H, J 11.8 Hz, CHHPh), 4.44 (app. q, 1H, J40 ,30 = J40 ,50 = J40 ,P
9.5 Hz, H-40), 4.37–4.34 (m, 1H, H-7), 4.27–4.25 (m, 1H, H-5),
4.24–4.20 (m, 1H, H-50), 4.07 (app. t, 1H, J30 ,20 9.5 Hz, H-30), 3.97
(dd, 1H, J8a,8b 13.1, J8a,7 1.7 Hz, H-8a), 3.86–3.78 (m, 5H, CO2CH3,
H-4, OH), 3.74 (s, 3H, PhOCH3), 3.62–3.56 (m, 4H, H-20, H-60a,
H-6, H-8b), 3.46–3.41 (m, 1H, H-60b), 3.28 (s, 3H, OCH3), 2.23 (dd,1H, J3eq,3ax 12.4, J3eq,4 4.5 Hz, H-3eq), 2.14 (app. t, J3ax,4 12.2 Hz,
H-3ax), 1.03–0.75 (m, 28H, TIPDS); 13C NMR (CDCl3): d 168.91 (s,
C@O), 159.17, 138.38 (s, 3C, Ar), 135.65 (s, JC,P 6.4 Hz, Ar), 135.42
(s, JC,P 7.5 Hz, Ar), 130.08 (s, Ar), 128.93, 128.58, 128.55, 128.43,
128.39, 128.14, 128.10, 127.97, 127.87, 127.81, 127.32, 127.13,
126.77, 113.83 (d, 24C, Ar), 99.12 (s, C-2), 97.92 (d, C-10), 79.85
(d, C-20), 79.12 (d, JC,P 4.2 Hz, C-30), 75.04 (d, JC,P 5.8 Hz, C-40),
74.85 (t, CH2Ph), 73.08 (d, C-4), 72.71 (t, CH2Ph), 71.73 (d, C-7),
71.32 (d, C-5), 71.20 (d, C-6), 70.65 (d, JC,P 3.3 Hz, C-50), 69.91,
69.86 (t, 2C, CH2Ph, POCH2Ph), 69.55 (t, JC,P 5.5 Hz, POCH2Ph),
62.90 (t, C-8), 60.24 (t, C-60), 55.19 (q, PhOCH3), 52.37 (q, CO2CH3),
51.14 (q, OCH3), 33.27 (t, C-3), 17.56, 17.49, 17.27, 17.15, 17.07 [q,
8C, Si-CH-(CH3)2], 14.19, 13.51, 12.98, 12.77 [d, 4C, Si-CH-(CH3)2];
31P NMR (CDCl3): d 0.67; ESI-TOF HRMS: m/z = 1253.5067; calcd
for C64H87O18PSi2Na+: 1253.5061.
3.17. 2,3-Di-O-benzyl-6-O-(diphenylphosphoryl)-a-D-gluco
pyranosyl-(1?5)-methyl [methyl 3-deoxy-4-O-(4-methoxy
benzyl)-7,8-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-a-D-
manno-oct-2-ulopyranosid]onate (23)
A suspension of compound 20 (34.0 mg, 0.035 mmol) and
4-N,N-dimethylaminopyridine (8.6 mg, 0.070 mmol) in dry CH2Cl2
(1.0 mL) containing 4 Å molecular sieves (50 mg) was stirred for
30 min at 0 C. Diphenyl phosphoryl chloride (7.6 lL, 0.037 mmol)
dissolved in dry CH2Cl2 (0.1 mL) was added dropwise to the cold
solution. After stirring for 20 min the reactive species was
destroyed with dry MeOH (0.1 mL). The solution was stirred for
10 min, ﬁltered over a pad of Celite, rinsed with CH2Cl2, and con-
centrated. The residue was puriﬁed by chromatography (n-hexane/
EtOAc 5:2) to provide 23 (40.6 mg, 96%) as a colorless oil; ½a20D
+76.5 (c 0.81, CHCl3); Rf 0.42 (n-hexane/EtOAc 3:2); 1H NMR
(CDCl3): d 7.36–7.21 (m, 16H, Ar), 7.19–7.11 (m, 6H, Ar), 6.85–
6.82 (m, 2H, Ar), 5.21 (d, 1H, J10 ,20 3.7 Hz, H-10), 4.92 (d, 1H, J
11.9 Hz, CHHPh), 4.82 (d, 1H, J 11.2 Hz, CHHPh), 4.77 (d, 1H, J
11.3 Hz, CHHPh), 4.64 (d, 1H, J 12.0 Hz, CHHPh), 4.49 (d, 1H, J
11.2 Hz, CHHPh), 4.46 (d, 1H, J 11.2 Hz, CHHPh), 4.42–4.39 (m,
1H, H-7), 4.22 (d, 1H, J5,4 2.3 Hz, H-5), 4.20–4.16 (m, 1H, H-50),
4.13–4.08 (m, 1H, H-60a), 3.99 (dd, 1H, J8a,8b 13.1, J8a,7 1.6 Hz, H-
8a), 3.91 (app. t, 1H, J30 ,20 = J30 ,40 9.4 Hz, H-30), 3.85 (ddd, 1H, J4,3ax
11.9, J4,3eq 4.5, H-4), 3.83 (s, 3H, CO2CH3), 3.76–3.71 (m, 1H,
H-60b), 3.70 (s, 3H, PhOCH3), 3.64–3.61 (m, 2H, H-6, H-8b), 3.52
(app. t, 1H, J40 ,50 9.7 Hz, H-40), 3.39 (dd, 1H, H-20), 3.29 (s, 3H,
OCH3), 2.25 (dd, 1H, J3eq,3ax 12.4 Hz, H-3eq), 2.11 (app. t, 1H,
H-3ax), 1.04–0.75 (m, 28 H, TIPDS); 13C NMR (CDCl3): d 168.78
(s, C@O), 159.24 (s, Ar), 150.51 (s, JC,P 7.0 Hz, Ar), 150.38 (s, JC,P
7.3 Hz, Ar), 138.93, 138.73, 130.11 (s, 3C, Ar), 129.68, 129.21,
128.28, 128.09, 127.84, 127.46, 127.04, 126.82, 125.43, 125.29 (d,
18C, Ar), 120.25 (d, JC,P 4.6 Hz, 2C, Ar), 120.05 (d, JC,P 5.2 Hz, 2C,
Ar), 113.82 (d, 2C, Ar), 99.12 (s, C-2), 98.59 (d, C-10), 80.30 (d,
C-30), 79.36 (d, C-20), 74.58 (t, CH2Ph), 73.55 (d, C-4), 72.11
(t, CH2Ph), 71.86 (d, C-5), 71.64 (d, C-7), 71.30 (d, C-6), 70.09 (t,
CH2Ph), 70.03 (d, JC,P 4.9 Hz, C-50), 69.30 (d, C-40), 67.25 (t, JC,P
5.9 Hz, C-60), 62.87 (t, C-8), 55.13 (q, PhOCH3), 52.37 (q, CO2CH3),
51.12 (q, OCH3), 33.00 (t, C-3), 17.54, 17.50, 17.48, 17.46, 17.27,
17.16, 17.07 [q, 8C, Si-CH-(CH3)2], 14.17, 13.47, 12.99, 12.76
[d, 4C, Si-CH-(CH3)2]; 31P NMR (CDCl3): d—10.34; ESI-TOF HRMS:
m/z = 1225.4760; calcd for C62H83O18PSi2Na+: 1225.4748.
3.18. 4-O-Acetyl-2,3-di-O-benzyl-6-O-(diphenylphosphoryl)-a-
D-glucopyranosyl-(1?5)-methyl [methyl 3-deoxy-4-O-(4-
methoxybenzyl)-7,8-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-a-D-manno-oct-2-ulopyranosid]onate (24)
Distilled acetic anhydride (9.4 lL, 0.100 mmol) and 4-N,
N-dimethylaminopyridine (0.3 mg, 0.003 mmol) were added
B. Pokorny et al. / Carbohydrate Research 391 (2014) 66–81 77successively at 0 C to a solution of 23 (30.0 mg, 0.025 mmol) in
dry pyridine (1.0 mL). After stirring for 2 h at 0 C the reaction
was quenched with dry MeOH (100 lL). Concentration of the solu-
tion and coevaporation with toluene gave a residue which was
puriﬁed by chromatography (n-hexane/EtOAc 2:1) to furnish 24
(29.8 mg, 96%) as a colorless oil; ½a20D +72.8 (c 0.47, CHCl3); Rf
0.25 (n-hexane/EtOAc 2:1); 1H NMR (CDCl3): d 7.35–7.12 (m,
22H, Ar), 6.82–6.79 (m, 2H, Ar), 5.26 (d, 1H, J10 ,20 3.7 Hz, H-10),
5.07 (app. t, 1H, J40 ,30 = J40 ,50 9.9 Hz, H-40), 4.90 (d, 1H, J 11.7 Hz,
CHHPh), 4.73 (d, 1H, J 11.3 Hz, CHHPh), 4.64 (d, 1H, J 11.8 Hz,
CHHPh), 4.60 (d, 1H, J 11.3 Hz, CHHPh), 4.50 (d, 1H, J 11.5 Hz,
CHHPh), 4.47 (d, 1H, J 11.5 Hz, CHHPh), 4.42–4.38 (m, 1H, H-50),
4.38–4.34 (m, 1H, H-7), 4.25 (d, 1H, J5,4 2.2 Hz, H-5), 4.03 (app. t,
1H, J30 ,20 9.7 Hz, H-30), 4.01 (dd, 1H, J8a,8b 13.0, J8a,7 1.6 Hz, H-8a),
3.97 (ddd, 1H, J60a,60b 11.3, J60a,P 5.4, J60a,50 2.3 Hz, H-60a), 3.88–3.83
(m, 4H, CO2CH3, H-4), 3.74–3.69 (m, 4H, H-60b, PhOCH3), 3.67
(dd, 1H, J8b,7 1.9 Hz, H-8b), 3.64 (d, 1H, J6,7 9.4 Hz, H-6), 3.50 (dd,
1H, H-20), 3.29 (s, 3H, OCH3), 2.27 (dd, 1H, J3eq,3ax 12.5, J3eq,4
4.6 Hz, H-3eq), 2.13 (app. t, 1H, J3ax,4 12.2 Hz, H-3ax), 1.86 (s, 3H,
COCH3), 1.03–0.78 (m, 28H, TIPDS); 13C NMR (CDCl3): d 169.18 (s,
COCH3), 168.94 (s, C-1), 159.23 (s, Ar), 150.70 (s, JC,P 7.2 Hz, Ar),
150.54 (s, JC,P 7.4 Hz, Ar), 138.51, 138.34, 129.97 (s, 3C, Ar),
129.62, 129.57, 129.28, 128.27, 128.16, 128.05, 127.53, 127.16,
126.76, 125.11, 125.02 (d, 18C, Ar), 120.21 (d, JC,P 5.1 Hz, 2C, Ar),
120.11 (d, JC,P 5.1 Hz, 2C, Ar), 113.82 (d, 2C, Ar), 99.15 (s, C-2),
97.84 (d, C-10), 79.60 (d, C-20), 78.36 (d, C-30), 74.19 (t, CH2Ph),
72.99 (d, C-4), 72.59 (t, CH2Ph), 71.73 (d, C-7), 71.19 (d, C-5),
71.17 (d, C-6), 69.95 (t, CH2Ph), 69.25 (d, C-40), 67.91 (d, JC,P
8.1 Hz, C-50), 66.64 (t, JC,P 5.5 Hz, C-60), 62.91 (t, C-8), 55.18 (q,
PhOCH3), 52.42 (q, CO2CH3), 51.16 (q, OCH3), 33.11 (t, C-3), 20.83
(q, COCH3), 17.52, 17.48, 17.45, 17.26, 17.15, 17.07 [q, 8C, Si-CH-
(CH3)2], 14.21, 13.55, 12.96, 12.79 [d, 4C, Si-CH-(CH3)2]; 31P NMR
(CDCl3): d–12.14; ESI-TOF HRMS: m/z = 1262.5295; calcd for
C64H85O19PSi2NH4+: 1262.5299.
3.19. 2,3-Di-O-benzyl-6-O-(dibenzylphosphoryl)-a-D-
glucopyranosyl-(1?5)-methyl [methyl 3-deoxy-7,8-O-(1,1,3,3-
tetraisopropyldisiloxane-1,3-diyl)-a-D-manno-oct-2-ulopyr
anosid]onate (25)
A solution of dibenzyl N,N-diisopropylphosphoramidite
(22.0 lL, 0.066 mmol) in dry CH2Cl2 (1.0 mL) was added under Ar
in two portions to an ice-cold solution of 14 (28.4 mg, 0.033 mmol)
and 1H-tetrazole (7.9 mg, 0.113 mmol) in dry CH2Cl2 (2.1 mL) and
stirred for 30 min at 0 C. m-Chloroperbenzoic acid (70 w%,
28.8 mg, 0.117 mmol) was added, and the solution was stirred
for 15 min. The solution was diluted with CH2Cl2 and extracted
with aq NaHCO3. The aqueous layer was extracted with CH2Cl2
(2  5 mL) and the combined organic phases were dried (Na2SO4)
and concentrated. The residue was puriﬁed by chromatography
(1:1 n-hexane/EtOAc containing 0.1% MeOH and 0.1% Et3N) to give
25 (23.4 mg, 63%) as a colorless oil: ½a20D +56.0 (c 0.72, CHCl3); Rf
0.49 (n-hexane/EtOAc 1:2); 1H NMR (CDCl3): d 7.35–7.26 (m,
20H, Ar), 5.10 (d, 1H, J10 ,20 3.5 Hz, H-10), 5.04–4.96 (m, 4H,
2  POCH2Ph), 4.87 (d, 1H, J 11.4 Hz, CHHPh), 4.80 (d, 1H, J
12.2 Hz, CHHPh), 4.78 (d, 1H, J 11.5 Hz, CHHPh), 4.74 (d, 1H, J
12.4 Hz, CHHPh), 4.45–4.42 (m, 1H, H-7), 4.25–4.20 (m, 1H, H-
60a), 4.16–4.04 (m, 5H, H-50, H-60b, H-4, H-5, H-8a), 3.96 (dd, 1H,
J8b,8a 12.8, J8b,7 1.9 Hz, H-8b), 3.87 (app. t, 1H, J30 ,20 = J30 ,40 9.0 Hz,
H-30), 3.79 (s, 3H, CO2CH3), 3.75 (d, 1H, J6,7 8.3 Hz, H-6), 3.50–
3.45 (m, 2H, H-20, H-40), 3.31 (s, 3H, OCH3), 2.98 (bs, 1H, OH),
2.14 (dd, 1H, J3eq,3ax 12.8, J3eq,4 4.9 Hz, H-3eq), 1.87 (app. t, J3ax,4
12.3 Hz, H-3ax), 1.04–0.80 (m, 28 H, TIPDS); 13C NMR (CDCl3): d
168.63 (s, C@O), 138.56, 138.23, (s, 2C, Ar), 135.66 (s, JC,P 6.5 Hz,
2C, Ar), 128.58, 128.55, 128.48, 128.35, 128.02, 127.99, 127.97,
127.78, 127.56, 127.32 (d, 20C, Ar), 99.04 (s, C-2), 99.01 (d, C-10),80.05 (d, C-30), 78.41 (d, C-20), 77.30 (d, C-5), 74.93 (t, CH2Ph),
72.76 (d, C-7), 72.49 (t, CH2Ph), 71.69, 71.63 (d, 2C, C-50, C-6),
69.60 (t, JC,P 6.1 Hz, POCH2Ph), 69.56 (t, JC,P 7.0 Hz, POCH2Ph),
69.50 (d, C-40), 66.61 (t, JC,P 7.7 Hz, C-60), 66.54 (d, C-4), 63.62 (t,
C-8), 52.39 (q, CO2CH3), 51.18 (q, OCH3), 35.93 (t, C-3), 17.57,
17.53, 17.50, 17.47, 17.31, 17.20, 17.12 [q, 8C, Si-CH-(CH3)2],
14.03, 13.52, 12.95, 12.78 [d, 4C, Si-CH-(CH3)2]; 31P NMR (CDCl3):
d—0.08; ESI-TOF HRMS: m/z = 1133.4487; calcd for C56H79O17PSi2-
Na+: 1133.4486.
Alternatively, a solution of 21 (39.9 mg, 0.032 mmol) in CH2Cl2
(2.0 mL) was treated with triﬂuoroacetic acid (99%, 0.25 mL) at 0 C
for 10 min. Dilution with toluene and azeotropic distillation affor-
ded a crude product which was immediately puriﬁed by chroma-
tography (n-hexane/EtOAc 1:1) providing 25 (31.8 mg, 88%) as a
colorless oil.
3.20. 2,3-Di-O-benzyl-6-O-(dibenzylphosphoryl)-a-D-gluco
pyranosyl-(1?5)-methyl (methyl 3-deoxy-a-D-manno-2-
octulopyranosid)onate (26)
A solution of 25 (6.4 mg, 0.006 mmol) in dry THF (1.2 mL) was
treated with TBAF (1 M in THF, 9 lL, 0.009 mmol) at ambient
temperature for 15 min. Addition of dry MeOH (1 mL) and concen-
tration provided a crude product which was puriﬁed by chroma-
tography (EtOAc) yielding 26 (4.6 mg, 92%) as a colorless oil; ½a20D
+96.0 (c 0.37, MeOH); Rf 0.34 (EtOAc); 1H NMR (MeOD): d 7.40–
7.25 (m, 20H, Ar), 5.18 (d, 1H, J10 ,20 3.5 Hz, H-10), 5.07–5.04 (m,
4H, 2  POCH2Ph), 4.91 (d, 1H, J 11.2 Hz, CHHPh), 4.84–4.82 (m,
1H, CHHPh), 4.75 (d, 1H, J 11.6 Hz, CHHPh), 4.72 (d, 1H, J 11.7 Hz,
CHHPh), 4.30–4.27 (m, 1H, H-60a), 4.26–4.18 (m, 2H, H-50, H-60b),
4.10–4.02 (m, 3H, H-4, H-5, H-7), 3.86 (dd, 1H, J30 ,20 9.6, J30 ,40
9.0 Hz, H-30), 3.74 (s, 3H, CO2CH3), 3.70 (dd, 1H, J8a,8b 11.2, J8a,7
2.9 Hz, H-8a), 3.67 (dd, 1H, J6,7 9.3, J6,5 1.1 Hz, H-6), 3.64 (dd, 1H,
J8b,7 4.4 Hz, H-8b), 3.51 (app. t, 1H, J40 ,50 9.3 Hz, H-40), 3.43 (dd,
1H, H-20), 3.21 (s, 3H, OCH3), 2.06–2.01 (m, 1H, H-3eq), 1.96 (app.
t, 1H, J3ax,3eq = J3ax,4 12.3 Hz, H-3ax); 13C NMR (MeOD): d 170.39
(s, C@O), 140.30, 139.34 (s, 2C, Ar), 135.82 (s, JC,P 6.6 Hz, Ar),
135.81 (s, JC,P 6.6 Hz, Ar), 129.67, 129.66, 129.43, 129.38, 129.24,
129.17, 129.09, 129.07, 128.87, 128.52 (d, 20C, Ar), 100.44
(s, C-2), 100.10 (d, C-10), 82.37 (d, C-30), 81.07 (d, C-20), 77.55 (d,
C-5), 76.26 (t, CH2Ph), 74.63 (t, CH2Ph), 73.18 (d, C-6), 72.47 (d,
JC,P 7.3 Hz, C-50), 71.18 (d, C-40), 70.82 (t, JC,P 5.9 Hz, 2C, 2  POCH2-
Ph), 69.98 (d, C-7), 68.23 (t, JC,P 5.5 Hz, C-60), 67.25 (d, C-4), 64.13 (t,
C-8), 52.94 (q, CO2CH3), 51.55 (q, OCH3), 36.47 (t, C-3); 31P NMR
(MeOD): d—1.20; ESI-TOF HRMS: m/z = 891.2966; calcd for
C44H53O16PNa+: 891.2963.
3.21. 6-O-Phosphono-a-D-glucopyranosyl-(1?5)-methyl 3-
deoxy-a-D-manno-oct-2-ulopyranosidonic acid (sodium salt)
(27)
A solution of 26 (8.2 mg, 0.009 mmol) in dry MeOH (1.0 mL)
was hydrogenated for 1 h in the presence of 10% Pd–C (1 mg) as
described for 13. The suspension was diluted with MeOH and
passed through a 0.45 lm syringe ﬁlter. The ﬁltrate was made neu-
tral by adding 0.1 M NaOMe (0.1 M in MeOH, 200 lL). Concentra-
tion of the ﬁltrate afforded the debenzylated methyl ester which
was saponiﬁed with 0.01 M aq NaOH (1.5 mL) at ambient temper-
ature for 1 h. The solution was made neutral by addition of DOWEX
50 H+ resin. The ion exchange resin was ﬁltered off and the ﬁltrate
was lyophilized. Puriﬁcation of the residue on a Bio-Gel PD10 col-
umn (H2O) and freeze-drying of pooled fractions provided 27
(5.2 mg, 98%) as a colorless amorphous solid; ½a20D +97.5 (c 0.49,
H2O); 1H NMR (D2O): d 5.11 (d, 1H, J10 ,20 4.1 Hz, H-10), 4.15–4.06
(m, 3H, H-4, H-7, H-50), 4.05–4.00 (m, 2H, H-5, H-60a), 3.90 (dd,
1H, J8a,8b 11.8, J8a,7 2.8 Hz, H-8a), 3.78–3.68 (ddd, 1H, J60b,60a 12.1, J
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(dd, 1H, J8b,7 6.1 Hz, H-8b), 3.59 (app. t, 1H, J40 ,50 9.7 Hz, H-40),
3.55–3.52 (m, 2H, H-6, H-20), 3.11 (s, 3H, OCH3), 1.96 (ddd, 1H,
J3eq,3ax 12.9, J3eq,4 4.9, J3eq,5 0.7 Hz, H-3eq), 1.82 (app. t, 1H, J3ax,4
12.5 Hz, H-3ax); 13C NMR data: see Table 1; 31P NMR (D2O): d
4.65; ESI-TOF HRMS: m/z = 493.0966; calcd for C15H26O16P-:
493.0964.
3.22. 4-O-Acetyl-2,3-di-O-benzyl-6-O-(diphenylphosphoryl)-a-
D-glucopyranosyl-(1?5)-methyl [methyl 3-deoxy-4-O-(4-
methoxybenzyl)-a-D-manno-oct-2-ulopyranosid]onate (28)
A solution of 24 (17.9 mg, 0.014 mmol) in dry CH2Cl2 was trea-
ted with triethylamine trihydroﬂuoride (117 lL, 0.719 mmol) for
4 h at ambient temperature. Another portion of triethylamine tri-
hydroﬂuoride (117 lL, 0.719 mmol) was added and stirring was
continued for 12 h. The colorless solution was added dropwise into
ice-cold aq NaHCO3 and extracted with CH2Cl2 (4  10 mL). The
combined organic layers were dried (MgSO4), ﬁltered, and concen-
trated. The residue was puriﬁed by chromatography (toluene/
EtOAc 1:1) which afforded 28 (11.8 mg, 82%) as a colorless oil;
½a20D +51.6 (c 1.13, CHCl3); Rf 0.24 (toluene/EtOAc 1:1); 1H NMR
(CDCl3, ref. to TMS at 0.00 ppm): d 7.37–7.10 (m, 22H, Ar), 6.84–
6.80 (m, 2H, Ar), 5.05 (app. t, 1H, J40 ,30 = J40 ,50 9.5 Hz, H-40), 5.04 (d,
1H, J10 ,20 3.5 Hz, H-10), 4.83 (d, 1H, J 11.8 Hz, CHHPh), 4.82 (d, 1H,
J 11.5 Hz, CHHPh), 4.69 (d, 1H, J 11.5 Hz, CHHPh), 4.61 (d, 1H, J
11.7 Hz, CHHPh), 4.44 (d, 1H, J 11.9 Hz, CHHPh), 4.37 (d, 1H, J
11.8 Hz, CHHPh), 4.19–4.15 (m, 2H, H-50, H-60a), 4.12 (bs, 1H, H-
5), 4.09–4.03 (m, 2H, H-60b, H-7), 4.00 (app. t, 1H, J30 ,20 9.5 Hz, H-
30), 3.85 (ddd, 1H, J4,3ax 11.9, J4,3eq 4.5, J4,5 2.4 Hz, H-4), 3.79 (dd,
1H, J8a,8b 11.1, J8a,7 3.4 Hz, H-8a), 3.76 (s, 3H, CO2CH3), 3.73 (s,
3H, PhOCH3), 3.63 (dd, 1H, J8b,7 4.9 Hz, H-8b), 3.59 (d, 1H, J6,7
9.2 Hz, H-6), 3.52 (dd, 1H, H-20), 3.18 (s, 3H, OCH3), 2.19 (dd, 1H,
J3eq,3ax 12.7 Hz, H-3eq), 1.98 (app. t, 1H, H-3ax), 1.92 (s, 3H, COCH3);
13C NMR (CDCl3): d 169.44 (s, COCH3), 168.46 (s, C-1), 159.13 (s,
Ar), 150.57 (s, JC,P 6.9 Hz, Ar), 150.45 (s, JC,P 6.5 Hz, Ar), 138.04,
136.99, 130.15 (s, 3C, Ar), 129.69, 129.64, 128.85, 128.75, 128.52,
128.49, 128.01, 127.83, 125.22, 125.14 (d, 18C, Ar), 120.16 (d, JC,P
4.6 Hz, 2C, Ar), 120.10 (d, JC,P 4.9 Hz, 2C, Ar), 113.85 (d, 2C, Ar),
99.15 (s, C-2), 98.49 (d, C-10), 80.60 (d, C-20), 79.04 (d, C-30),
75.20 (t, CH2Ph), 74.74 (t, CH2Ph), 73.98 (d, C-5), 72.95 (d, C-4),
72.39 (d, C-6), 69.89 (t, CH2Ph), 69.82 (d, C-40), 69.02 (d, JC,P
8.3 Hz, C-50), 68.59 (d, C-7), 67.07 (t, JC,P 5.5 Hz, C-60), 63.96 (t,
C-8), 55.19 (q, PhOCH3), 52.55 (q, CO2CH3), 51.01 (q, OCH3), 32.66
(t, C-3), 20.84 (q, COCH3); 31P NMR (CDCl3): d–11.95; ESI-TOF
HRMS: m/z = 1020.3773; calcd for C52H59O18PNH4+: 1020.3777.
3.23. 4-O-Acetyl-2,3-di-O-benzyl-6-O-(diphenylphosphoryl)-a-
D-glucopyranosyl-(1?5)-methyl [methyl 3-deoxy-4-O-(4-
methoxybenzyl)-a-D-lyxo-hept-2-ulopyranosid]onate (29)
A solution of 28 (27.0 mg, 0.027 mmol) in dry CH2Cl2 (3.5 mL)
was treated with sodium periodinate on silica (15 w%, 77 mg,
0.054 mmol) for 1.5 h at 10 C under light protection. Excessive
reagent was destroyed with ethylene glycol (3 w% in water,
56 lL, 0.027 mmol). The mixture was diluted with CHCl3 and
water, the phases were separated and the aqueous phase was
extracted with CH2Cl2 (3  10 mL). The combined organic phases
were dried (MgSO4), ﬁltered, and concentrated. The residue was
treated with sodium borohydride (3.1 mg, 0.081 mmol) in dry
MeOH (3.5 mL) at 5 C for 30 min. The mixture was partitioned
between EtOAc and aq NH4Cl, the aqueous phase was extracted
with EtOAc (3  5 mL) and the combined organic phases were
dried (MgSO4). Filtration and concentration afforded a crude prod-
uct which was puriﬁed by HP-column chromatography (toluene/
EtOAc 2:1) providing 29 (9.5 mg, 36%) as a colorless oil: ½a20D+48.0 (c 0.42, CHCl3); Rf 0.32 (toluene/EtOAc 1:1); 1H NMR (CDCl3,
ref. to TMS at 0.00 ppm): d 7.36–7.19 (m, 16H, Ar), 7.18–7.10 (m,
6H, Ar), 6.84–6.81 (m, 2H, Ar), 5.03 (app. t, 1H, J40 ,30 = J40 ,50 9.8 Hz,
H-40), 4.98 (d, 1H, J10 ,20 3.4 Hz, H-10), 4.83 (d, 1H, J 11.5 Hz, CHHPh),
4.79 (d, 1H, J 11.5 Hz, CHHPh), 4.66 (d, 1H, J 11.5 Hz, CHHPh), 4.61
(d, 1H, J 11.8 Hz, CHHPh), 4.47 (d, 1H, J 11.8 Hz, CHHPh), 4.38 (d,
1H, J 11.6 Hz, CHHPh), 4.22–4.18 (m, 1H, H-50), 4.15 (ddd, J60a,60b
11.1, J60a,P 6.1, J60a,50 2.4 Hz, H-60a), 4.03–3.96 (m, 3H, H-30, H-60b,
H-5), 3.90–3.84 (m, 2H, H-4, H-7a), 3.82–3.76 (m, 4H, H-7b,
CO2CH3), 3.74–3.70 (m, 4H, H-6, PhOCH3), 3.49 (dd, 1H, J20 ,30 9.6,
H-20), 3.20 (s, 3H, OCH3), 2.99 (bs, 1H, OH), 2.23 (dd, 1H, J3eq,3ax
12.7, J3eq,4 4.3 Hz, H-3eq), 2.02 (app. t, 1H, J3ax,4 12.2 Hz, H-3ax),
1.90 (s, 3H, COCH3); 13C NMR (CDCl3): d 169.41 (s, COCH3),
168.56 (s, C-1), 159.16 (s, Ar), 150.60 (s, JC,P 7.5 Hz, Ar), 150.47 (s,
JC,P 6.6 Hz, Ar), 138.15, 137.11, 130.14 (s, 3C, Ar), 129.68, 129.63,
128.92, 128.69, 128.47, 128.45, 128.40, 127.95, 127.75, 125.20,
125.12 (d, 18C, Ar), 120.15 (d, 2C, JC,P 5.1 Hz, Ar), 120.09 (d, 2C,
JC,P 5.3 Hz, Ar), 113.85 (d, 2C, Ar), 99.15 (s, C-2), 98.22 (d, C-10),
80.54 (d, C-20), 78.95 (d, C-30), 75.20 (t, CH2Ph), 74.56 (t, CH2Ph),
73.59 (d, C-5), 73.09 (d, C-4), 72.70 (d, C-6), 69.99 (t, CH2Ph),
69.66 (d, C-40), 68.97 (d, JC,P 7.8 Hz, C-50), 67.04 (t, JC,P 5.5 Hz,
C-60), 60.68 (t, C-7), 55.19 (q, PhOCH3), 52.60 (q, CO2CH3), 51.01
(q, OCH3), 32.71 (t, C-3), 20.81 (q, COCH3); 31P NMR (CDCl3):
d –11.96; ESI-TOF HRMS m/z: 990.3668; calcd for C51H57O17PNH4+:
990.3672.
3.24. 6-O-Phosphono-a-D-glucopyranosyl-(1?5)-(methyl 3-
deoxy-a-D-lyxo-hept-2-ulopyranosid)onic acid (sodium salt)
(30)
A suspension of compound 29 (8.0 mg, 0.008 mmol) in dry
MeOH was hydrogenated for 36 h and processed as described for
13. The solution obtained upon removal of the catalyst was con-
centrated. The residue was dried and dissolved in dry MeOH
(1.0 mL). PtO2 (1 mg) was added under an Ar atmosphere and
hydrogenation was continued for 4 h at rt. The suspension was
diluted with MeOH and passed through a 0.45 lm syringe ﬁlter.
The ﬁltrate was concentrated, and the residue was stirred with
0.01 M aq. NaOH (3.0 mL) at ambient temperature for 3 h. The
solution was neutralized by addition of DOWEX 50 H+ resin, the
ion-exchange resin was ﬁltered off and the ﬁltrate was lyophilized.
Puriﬁcation of the residue by HILIC (SeQuant ZIC-HILIC, 5 lm,
250  10 mm pre-packed from Merck, 5:1? 2:3 acetonitrile/
water) followed by desalting on a PD10 column (H2O) afforded
30 (2.2 mg, 52%) as an amorphous colorless solid: ½a20D +69.2 (c
0.39, D2O); 1H NMR (D2O): d 4.88 (d, 1H, J10 ,20 4.0 Hz, H-10), 4.19–
4.15 (m, 1H, H-50), 4.12 (ddd, 1H, J4,3ax 12.3, J4,3eq 4.8, J4,5 3.0 Hz,
H-4), 4.05 (ddd, 1H, J60a,60b 11.6, J 6.2, J 3.2 Hz, H-60a), 3.96 (dd,
1H, J7a,7b 11.5, J7a,6 8.3 Hz, H-7a), 3.89–3.85 (m, 2H, H-5, H-60b),
3.81 (dd, 1H, J7b,6 4.4 Hz, H-7b), 3.75 (br dd, 1H, H-6), 3.72 (app.
t, 1H, J30 ,20 = J30 ,40 9.7 Hz, H-30), 3.53 (app. t, 1H, J40 ,50 9.7 Hz, H-40),
3.51 (dd, 1H, H-20), 3.14 (s, 3H, OCH3), 2.01 (dd, 1H, J3eq,3ax 13.0,
H-3eq), 1.83 (app. t, 1H, H-3ax); 13C NMR data: see Table 1; 31P
NMR (D2O): d 2.40; ESI-TOF HRMS: m/z = 463.0857; calcd for
C14H24O15P-: 463.0858.
3.25. 2,3-Di-O-benzyl-6-O-(dibenzylphosphoryl)-a-D-
glucopyranosyl-(1?5)-methyl (methyl 3-deoxy-a-D-lyxo-hept-
2-ulopyranosid)onate (31)
Sodium metaperiodinate on silica (15 w%, 70 mg, 0.049 mmol)
was added to a solution of 26 (21.4 mg, 0.025 mmol) in dry CH2Cl2
(3.0 mL) at 0 C under light protection. The suspension was
allowed to warm up to ambient temperature during 1.5 h. Exces-
sive reagent was destroyed by addition of aq ethylene glycol
(3 w%, 51 lL, 0.025 mmol). The product was partitioned between
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(2  5 mL), and the combined organic layers were dried (MgSO4)
and concentrated. The crude aldehyde was dissolved in dry MeOH
(3.0 mL) and treated with sodium borohydride (2.8 mg,
0.074 mmol) at 0 C for 10 min. The solution was extracted with
CH2Cl2 (3  10 mL) and aq NH4Cl, and the organic phase was dried
(MgSO4), and concentrated. The crude material was puriﬁed by HP-
column chromatography (n-hexane/EtOAc 1:4? 0:1) to yield 31
(9.6 mg, 47%) as a colorless oil; ½a20D +29.2 (c 0.99, CHCl3); Rf 0.59
(EtOAc); 1H NMR (CDCl3): d 7.42–7.28 (m, 20H, Ar), 5.03–4.95
(m, 4H, 2  POCH2Ph), 4.93 (d, 1H, J 11.6 Hz, CHHPh), 4.88 (d, 1H,
J 11.3 Hz, CHHPh), 4.85 (d, 1H, J 11.7 Hz, CHHPh), 4.81 (d, 1H,
J10 ,20 3.5 Hz, H-10), 4.65 (d, 1H, J 11.9 Hz, CHHPh), 4.23 (ddd, 1H,
J60a,60b 11.8, J 8.1, J 5.0 Hz, H-60a), 4.09 (ddd, 1H, J 9.2, J 2.1 Hz,
H-60b), 4.06–4.00 (m, 1H, H-4), 3.94–3.76 (m, 9H, H-30, H-50, H-5,
H-6, H-7a, H-7b, CO2CH3), 3.52–3.36 (m, 4H, H-20, H-40, 2  OH),
3.21 (s, 3H, OCH3), 3.21–3.18 (m, 1H, OH), 2.19 (ddd, 1H, J3eq,3ax
12.5, J3eq,4 4.6, J3eq,5 0.6 Hz, H-3eq), 1.72–1.62 (m, 1H, H-3ax);
13C NMR (CDCl3): d 168.34 (s, C@O), 138.35, 136.76 (s, 2C, Ar),
135.53 (s, JC,P 6.5 Hz, Ar), 135.51 (s, JC,P 6.8 Hz, Ar), 128.85,
128.67, 128.63, 128.60, 128.52, 128.03, 128.02, 127.99 (d, 20C,
Ar), 100.37 (d, C-10), 99.02 (s, C-2), 80.50 (d, C-30), 79.22 (d, C-5),
79.06 (d, C-20), 75.61 (t, CH2Ph), 74.77 (t, CH2Ph), 72.03 (d, JC,P
5.7 Hz, C-50), 71.66 (d, C-6), 69.87 (d, C-40), 69.75 (t, JC,P 5.4 Hz,
POCH2Ph), 69.69 (t, JC,P 5.6 Hz, POCH2Ph), 66.27 (t, JC,P 5.1 Hz,
C-60), 66.03 (d, C-4), 60.59 (t, C-7), 52.58 (q, CO2CH3), 51.06 (q,
OCH3), 36.32 (t, C-3); 31P NMR (CDCl3): d 0.04; ESI-TOF HRMS:
m/z = 861.2855; calcd for C43H51O15PNa+: 861.2858.
Deprotection of 31: A suspension of compound 31 (7.4 mg,
0.009 mmol) and 10% Pd–C (1 mg) in dry MeOH (1.0 mL) was
hydrogenated for 1 h at room temperature as described for 13.
The suspension was diluted with MeOH, passed through a
0.45 lm syringe ﬁlter and the ﬁltrate was made neutral by addi-
tion of 0.1 M NaOMe in MeOH (100 lL). Concentration afforded
the debenzylated methyl ester which was saponiﬁed with 0.01 M
NaOH (1.5 mL) at ambient temperature for 8 h. The solution was
neutralized by addition of DOWEX 50 H+ ion-exchange resin. The
resin was ﬁltered off and the ﬁltrate was lyophilized. Puriﬁcation
of the residue on BioGel PD10 (H2O) and freeze-drying of pooled
fractions provided 30 (3.9 mg, 87%) as a colorless amorphous solid.
3.26. Methyl (methyl 4,5;7,8-di-O-isopropylidene-D-glycero-a-D-
talo-oct-2-ulopyranosid)onate (34)
Sodium hydride (0.13 g, 3.28 mmol) was added in small por-
tions to an ice-cold solution of methyl (3-O-acetyl-4,5;7,8-di-O-
isopropylidene-D-glycero-a-D-galacto-oct-2-ulopyranosyl)onate 32
(0.85 g, 2.19 mmol) and iodomethane (0.16 mL, 2.63 mmol) in
dry DMF (10 mL). After vigorous stirring at 0 C for 45 min, cleav-
age of the 3-O-acetyl group was induced by addition of dry MeOH
(15 mL) forming NaOMe in situ. After 15 h at ambient temperature
the solution was partitioned between EtOAc and aq NH4Cl. The
aqueous phase was extracted with EtOAc (3  50 mL) and the com-
bined organic phases were dried (MgSO4), ﬁltered, and concen-
trated. The crude product was puriﬁed by chromatography
(toluene/EtOAc 2:1) affording 33 (680 mg, 86%) as a colorless oil
with minor impurities.
A solution of 33 (0.67 g, 1.85 mmol) in dry CH2Cl2 (15 mL) was
treated with Dess-Martin periodinane (1.57 g, 3.70 mmol) at ambi-
ent temperature for 17 h. The mixture was dissolved in Et2O
(150 mL) and aq NaHCO3 (50 mL) containing Na2S2O3 (5 g) and
was stirred for 30 min. The organic phase was washed with aq
NaHCO3, dried (MgSO4), ﬁltered, and concentrated. The residue
was dissolved in dry MeOH (15 mL) and treated with borane
ammonia complex (0.08 g, 2.50 mmol) at 0 C for 15 min. After
dilution with dry MeOH the solvent was removed. The residuewas partitioned between CH2Cl2 and aq NH4Cl and the aqueous
layer was extracted with CH2Cl2 (2  50 mL). The combined
organic phases were dried (MgSO4), ﬁltered, and concentrated.
Chromatography of the residue (2:1 toluene/EtOAc) gave 34
(0.50 g, 75% based on 33) as a colorless oil; ½a20D +57.0 (c 1.19,
CHCl3); Rf 0.40 (toluene/EtOAc 1:1); 1H NMR (CDCl3): d 4.46 (dd,
1H, J4,5 6.7, J4,3 4.2 Hz, H-4), 4.44 (ddd, 1H J7,6 7.8, J7,8a 6.1, J7,8b
4.6 Hz, H-7), 4.33 (dd, 1H, J5,6 2.6 Hz, H-5), 4.16 (dd, 1H, J8a,8b 8.8,
H-8a), 4.10 (dd, 1H, H-8b), 3.92 (dd, 1H, J3,OH 7.8, H-3), 3.82 (s,
3H, CO2CH3), 3.72 (dd, 1H, H-6), 3.25 (s, 3 H, OCH3), 3.01 (d, 1H,
OH), 1.51 [s, 3H, C(CH3)], 1.44 [s, 3H, C(CH3)], 1.38 [s, 6H,
2  C(CH3)]; 13C NMR (CDCl3): d 167.98 (s, C@O), 109.95 [s,
C(CH3)2], 109.41 [s, C(CH3)2], 99.92 (s, C-2), 73.90 (d, C-7), 72.40
(d, C-4), 71.44 (d, C-5), 69.75 (d, C-6), 68.84 (d, C-3), 66.77
(t, C-8), 52.62 (q, CO2CH3), 51.22 (q, OCH3), 26.90, 25.37, 25.33,
25.18 [q, 4C, 4  C(CH3)]; ESI-TOF HRMS: m/z = 385.1464; calcd
for C16H26O9Na+: 385.1469.
3.27. Methyl (methyl 3-O-benzyl-4,5;7,8-di-O-isopropylidene-D-
glycero-a-D-talo-oct-2-ulopyranosid)onate (35)
A solution of 34 (184 mg, 0.508 mmol) in dry DMF (8.5 mL) was
treated with sodium hydride (41 mg, 1.016 mmol) and stirred for
5 min at 0 C. Benzyl bromide (121 lL, 1.016 mmol) was added
dropwise and the solution was stirred for 40 min at 0 C. Dry MeOH
(1.1 mL) was added to the cold mixture and after 5 min the solu-
tion was neutralized with DOWEX 50 H+ resin. The resin was ﬁl-
tered off and washed thoroughly with EtOAc. The ﬁltrate was
washed successively with aq NaHCO3 and brine, dried (MgSO4),
and concentrated. The crude product was puriﬁed by chromatogra-
phy (toluene/EtOAc 5:1) providing 35 (217 mg, 94%) as a colorless
oil: ½a20D 18.5 (c 1.04, CHCl3); Rf 0.29 (toluene/EtOAc 4:1); 1H NMR
(CDCl3): d 7.37–7.26 (m, 5H, Ar), 4.80 (s, 2H, CH2Ph), 4.42 (dd, 1H,
J4,5 7.7, J4,3 3.6 Hz, H-4), 4.40 (ddd, 1H, J7,6 7.3, J7,8a 6.3, J7,8b 4.9 Hz,
H-7), 4.30 (dd, 1H, J5,6 2.2 Hz, H-5), 4.12 (dd, 1H, J8a,8b 8.9, Hz,
H-8a), 4.02 (dd, 1H, H-8b), 3.77 (s, 3H, CO2CH3), 3.61 (d, 1H,
H-3), 3.55 (dd, 1H, H-6), 3.30 (s, 3H, OCH3), 1.54 [s, 3H, C(CH3)],
1.41 [s, 3H, C(CH3)], 1.36 [s, 3H, C(CH3)], 1.34 [s, 3H, C(CH3)]; 13C
NMR (CDCl3): d 167.04 (s, C@O), 137.62 (s, Ar), 128.43, 128.30,
127.72 (d, 5C, Ar), 110.60 [s, C(CH3)2], 109.11 [s, C(CH3)2], 101.90
(s, C-2), 75.91 (d, C-3), 73.90 (d, C-4), 73.62 (t, CH2Ph), 73.42 (d,
C-7), 72.38 (d, C-5), 70.06 (d, C-6), 66.78 (t, C-8), 52.36 (q, CO2CH3),
50.83 (q, OCH3), 26.84, 25.28, 25.26, 25.07 [q, 4C, 4  C(CH3)];
ESI-TOF HRMS: m/z = 470.2389; calcd for C23H32O9NH4+: 470.2385.
3.28. Methyl (methyl 3-O-benzyl-7,8-O-isopropylidene-D-
glycero-a-D-talo-oct-2-ulopyranosid)onate (36)
A solution of 35 (101 mg, 0.223 mmol), p-toluenesulfonic acid
monohydrate (42 mg, 0.223 mmol) and distilled water (84 lL,
4.460 mmol) in dry acetone (3.0 mL) was stirred at ambient tem-
perature for 15 min. Et3N (160 lL) was added, the solution was
stirred for 30 min, and concentrated. The crude product was puri-
ﬁed by chromatography (toluene/EtOAc 2:1) affording 36 (65 mg,
71%) as a colorless amorphous solid; ½a20D +36.8 (c 0.80, CHCl3);
Rf 0.41 (toluene/EtOAc 1:1); 1H NMR (CDCl3): d 7.35–7.27 (m, 3H,
Ar), 7.24–7.21 (m, 2H, Ar), 4.81 (d, 1H, J 10.9 Hz, CHHPh), 4.56 (d,
1H, J 11.0 Hz, CHHPh), 4.48 (ddd, 1H, J7,6 7.9, J7,8a 6.3, J7,8b 5.1 Hz,
H-7), 4.18 (dd, 1H, J8a,8b 8.8 Hz, H-8a), 4.08 (dd, 1H, J3,4 3.3, J3,5
1.2 Hz, H-3), 4.05 (dd, 1H, H-8b), 3.96 (app. td, 1H, J4,OH 9.8, J4,5
3.4 Hz, H-4), 3.93–3.89 (m, 1H, H-5), 3.71 (s, 3H, CO2CH3), 3.55
(dd, 1H, J6,5 1.2 Hz, H-6), 3.22 (s, 3H, OCH3), 3.06 (d, 1H, JOH,5
11.8 Hz, OH), 2.92 (d, 1H, JOH,4 9.8 Hz, OH), 1.42 [s, 3H, C(CH3)],
1.37 [s, 3H, C(CH3)]; 13C NMR (CDCl3): d 167.36 (s, C@O), 136.93
(s, Ar), 128.55, 128.15, 127.78 (d, 5C, Ar), 109.19 [s, C(CH3)2],
100.70 (s, C-2), 79.86 (d, C-3), 76.55 (t, CH2Ph), 73.35 (d, C-7),
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CO2CH3), 51.09 (q, OCH3), 26.73, 25.31 [q, 2C, 2  C(CH3)]; ESI-TOF
HRMS: m/z = 435.1624; calcd for C20H28O9Na+: 435.1626.
3.29. Methyl [methyl 3-O-benzyl-7,8-O-isopropylidene-4-O-(4-
methoxybenzyl)-D-glycero-a-D-talo-oct-2-ulopyranosid]onate
(37)
A mixture of 36 (64 mg, 0.155 mmol) and dibutyltin oxide
(42 mg, 0.171 mmol) in dry toluene (3.5 mL) was heated to reﬂux
using a Dean-Stark apparatus for 3 h. The solution was allowed
to cool to ambient temperature followed by consecutive addition
of dry DMF (144 lL, 1.862 mmol), 4-methoxybenzyl chloride
(105 lL, 0.776 mmol), and tetrabutylammonium iodide (63 mg,
0.171 mmol). After stirring at 60 C for 16 h the mixture was
diluted with EtOAc and washed successively with HCl (1 M), aq
NaHCO3, aq Na2S2O3 (50 g/L), and brine. The organic phase was
dried (MgSO4), ﬁltered, and concentrated. Chromatography of the
residue (toluene/EtOAc 5:1) gave 37 (67 mg, 81%) as a colorless
oil; ½a20D +28.0 (c 0.90, CHCl3); Rf 0.51 (toluene/EtOAc 2:1); 1H
NMR (CDCl3): d 7.35–7.24 (m, 5H, Ar), 7.22–7.20 (m, 2H, Ar),
6.91–6.88 (m, 2H, Ar), 4.97 (d, 1H, J 10.7 Hz, CHHPh), 4.81 (d, 1H,
J 11.3 Hz, CHHPh), 4.56–4.51 (m, 1H, H-7), 4.52 (d, 1H, J 11.2 Hz,
CHHPh), 4.49 (d, 1H, J 10.7 Hz, CHHPh), 4.19 (dd, 1H, J8a,8b 8.8,
J8a,7 6.3 Hz, H-8a), 4.17–4.14 (m, 2H, H-3, H-5), 4.04 (dd, 1H, J8b,7
5.4 Hz, H-8b), 3.82–3.80 (m, 1H, H-4), 3.81 (s, 3H, PhOCH3), 3.68
(s, 3H, CO2CH3), 3.68 (d, 1H, JOH,5 10.1 Hz, OH), 3.46 (dd, 1H, J6,7
7.7, J6,5 1.3 Hz, H-6), 3.19 (s, 3 H, OCH3), 1.43 [s, 3H, C(CH3)], 1.37
[s, 3H, C(CH3)]; 13C NMR (CDCl3): d 167.47 (s, C@O), 159.27,
137.22, 130.03 (s, 3C, Ar), 129.20, 128.36, 128.19, 127.95, 113.86
(d, 9C, Ar), 109.07 [s, C(CH3)2], 100.79 (s, C-2), 78.20 (d, C-3),
75.99 (t, CH2Ph), 74.04 (d, C-6), 73.62, 73.60 (d, 2C, C-4, C-7),
69.36 (t, CH2Ph), 66.87 (t, C-8), 65.84 (d, C-5), 55.26 (q, PhOCH3),
52.44 (q, CO2CH3), 51.07 (q, OCH3), 26.68, 25.40 [q, 2C, 2  C(CH3)];
ESI-TOF HRMS:m/z = 550.2641; calcd for C28H36O10NH4+: 550.2647.
3.30. 2,3-Di-O-benzyl-4,6-O-benzylidene-a-D-glucopyranosyl-
(1?5)-methyl [methyl 3-O-benzyl-7,8-O-isopropylidene-4-O-(4-
methoxybenzyl)-D-glycero-a-D-talo-oct-2-ulopyranosid]onate
(38)
A suspension of predried compounds 37 (34.6 mg, 0.065 mmol)
and 10 (52.3 mg, 0.084 mmol) in dry CH2Cl2 (1.0 mL) containing
4 Å molecular sieves was stirred at ambient temperature for 1 h.
At 30 C TMSOTf (0.6 lL, 0.004 mmol) in dry CH2Cl2 (0.2 mL)
was added in two portions within an interval of 1 h. The mixture
was kept at 30 C for 10 min after complete addition. The pro-
moter was destroyed by addition of Et3N (19 lL, 0.130 mmol) in
dry CH2Cl2 (0.3 mL). The suspension was allowed to warm up to
ambient temperature, ﬁltered over a pad of Celite, rinsed with
CH2Cl2, and the ﬁltrate was concentrated. Product 38 (26.0 mg,
42%) was isolated by chromatography (n-hexane/EtOAc 3:1) as a
colorless oil; ½a20D +27.8 (c 0.68, CHCl3); Rf 0.45 (n-hexane/EtOAc
3:2, HPTLC); 1H NMR (CDCl3): d 7.41–7.32 (m, 9H, Ar), 7.31–7.20
(m, 10H, Ar), 7.08–7.03 (m, 3H, Ar), 6.91–6.88 (m, 2H, Ar), 5.43
(s, 1H, CHPh), 5.20 (d, 1H, J10 ,20 3.8 Hz, H-10), 5.18 (d, 1H, J
11.9 Hz, CHHPh), 4.91 (d, 1H, J 11.6 Hz, CHHPh), 4.78 (ddd, 1H,
J7,6 9.6, J7,8b 6.1, J7,8a 3.5 Hz, H-7), 4.73 (d, 1H, J 12.0 Hz, CHHPh),
4.69 (d, 1H, J 11.8 Hz, CHHPh), 4.62 (d, 1H, J 11.6 Hz, CHHPh),
4.54 (d, 1H, J 11.3 Hz, CHHPh), 4.49 (app. dt, 1H, J50 ,60b = J50 ,40 9.9,
J50 ,60a 5.1 Hz, H-50), 4.48 (d, 1H, J 11.7 Hz, CHHPh), 4.20 (d, 1H, J
11.2 Hz, CHHPh), 4.13–4.12 (m, 2H, H-3, H-5), 3.93 (dd, 1H, J8a,8b
8.9 Hz, H-8a), 3.91 (dd, 1H, J60a,60b 10.0 Hz, H-60a), 3.88 (app. t, 1H,
J30 ,20 = J30 ,40 9.4 Hz, H-30), 3.84 (dd, 1H, H-8b), 3.78 (s, 3H, PhOCH3),
3.78–3.77 (m, 1H, H-4), 3.70 (s, 3H, CO2CH3), 3.57 (dd, 1H, H-20),
3.51 (app. t, 1H, H-60b), 3.48 (app. t, 1H, H-40), 3.38 (dd, 1H, J6,51.1 Hz, H-6), 3.18 (s, 3H, OCH3), 1.36 [s, 3H, C(CH3)], 1.23 [s, 3H,
C(CH3)]; 13C NMR (CDCl3): d 167.72 (s, C@O), 159.33, 139.12,
138.75, 138.62, 137.97, 129.74 (s, 6C, Ar), 129.11, 128.56, 128.13,
128.11, 128.08, 127.94, 127.83, 127.75, 127.31, 127.29, 127.22,
127.02, 126.16, 114.05 (d, 24C, Ar), 109.19 [s, C(CH3)2], 101.59 (s,
C-2), 101.02 (d, CHPh), 99.98 (d, C-10), 83.01 (d, C-40), 78.87 (d, C-
20), 77.55 (d, C-30), 76.96 (d, C-3), 75.38 (t, CH2Ph), 75.22 (d, C-4),
74.64 (t, CH2Ph), 73.83 (d, C-6), 72.79 (d, C-5), 71.96 (d, C-7),
71.75 (t, CH2Ph), 70.93 (t, CH2Ph), 69.16 (t, C-60), 67.16 (t, C-8),
62.61 (d, C-50), 55.23 (q, PhOCH3), 52.36 (q, CO2CH3), 51.11
(q, OCH3), 27.37, 25.34 [q, 2C, 2  C(CH3)]; ESI-TOF HRMS:
m/z = 985.3979; calcd for C55H62O15Na+: 985.3981.
3.31. 2,3-Di-O-benzyl-a-D-glucopyranosyl-(1?5)-methyl
[methyl 3-O-benzyl-4-O-(4-methoxybenzyl)-D-glycero-a-D-talo-
oct-2-ulopyranosid]onate (39)
A suspension of 38 (26.4 mg, 0.027 mmol) and p-toluenesul-
fonic acid monohydrate (0.9 mg, 0.005 mmol) in dry MeOH
(1.5 mL) was kept at 0 C for 1 h followed by stirring at ambient
temperature for 24 h. Et3N (10 lL) was added to the mixture, stir-
ring was continued for 10 min, and the solution was concentrated.
Chromatography of the residue afforded 39 (16.0 mg, 70%) as a col-
orless oil; ½a20D +53.8 (c 0.71, CHCl3); Rf 0.16 (n-hexane/EtOAc 1:4);
1H NMR (CDCl3): d 7.39–7.27 (m, 16H, Ar), 7.25–7.21 (m, 1H, Ar),
6.91–6.89 (m, 2H, Ar), 5.01 (d, 1H, J 12.0 Hz, CHHPh), 4.92 (d, 1H,
J 11.5 Hz, CHHPh), 4.81 (d, 1H, J 11.5 Hz, CHHPh), 4.80 (d, 1H,
J10 ,20 3.4 Hz, H-10), 4.79 (d, 1H, J 11.0 Hz, CHHPh), 4.61 (d, 1H, J
12.4 Hz, CHHPh), 4.59 (d, 1H, J 11.9 Hz, CHHPh), 4.54 (d, 1H, J
11.8 Hz, CHHPh), 4.52 (d, 1H, J 11.9 Hz, CHHPh), 4.20–4.15 (m,
1H, H-7), 4.12 (d, 1H, JOH,7 6.0 Hz, OH), 4.02–3.99 (m, 2H, H-3,
H-5), 3.83–3.79 (m, 4H, PhOCH3, H-50), 3.78–3.72 (m, 3H, H-30,
H-4, H-8a), 3.68 (s, 3H, CO2CH3), 3.66–3.62 (m, 1H, H-8b), 3.61
(dd, 1H, J6,7 9.2, J6,5 1.7 Hz, H-6), 3.44 (dd, 1H, J20 ,30 9.6 Hz, H-20),
3.33–3.28 (m, 1H, H-40), 3.26–3.19 (m, 2H, H-60a, H-60b), 3.16 (s,
3H, OCH3), 1.85 (bt, 1H, JOH,8a = JOH,8b 6.5 Hz, OH), 1.80 (bt, 1H,
JOH,60a = JOH,60b 6.0 Hz, OH), 0.88 (d, 1H, JOH,40 7.5 Hz, OH); 13C NMR
(CDCl3): d 167.81 (s, C@O), 159.47, 139.09, 138.59, 137.05,
129.53 (s, 5C, Ar), 129.27, 128.72, 128.71, 128.51, 128.48, 128.32,
127.99, 127.74, 127.35, 126.29, 113.99 (d, 19C, Ar), 101.25 (d,
C-10), 101.10 (s, C-2), 82.07 (d, C-30), 80.31 (d, C-20), 76.56, 75.82
(d, 2C, C-3, C-5), 75.26 (t, CH2Ph), 75.07 (d, C-4), 75.00 (t, CH2Ph),
74.39 (t, CH2Ph), 72.55 (d, C-40), 71.79 (d, C-6), 71.61 (d, C-50),
70.85 (t, CH2Ph), 68.05 (d, C-7), 64.12 (t, C-8), 62.45 (t, C-60),
55.27 (q, PhOCH3), 52.46 (q, CO2CH3), 51.04 (q, OCH3); ESI-TOF
HRMS: m/z = 857.3351; calcd for C45H54O15Na+: 857.3355.
3.32. a-D-Glucopyranosyl-(1?5)-sodium (methyl D-glycero-a-D-
talo-oct-2-ulopyranosid)onate (40)
A suspension of 39 (5.9 mg, 0.007 mmol) in dry MeOH (1 mL)
was hydrogenated for 4 h with 10% Pd–C (1 mg) as described for
13. Fresh catalyst (1 mg) was added and stirring was continued
under H2 for 14 h. The suspension was diluted with MeOH and
passed through a 0.45 lm syringe ﬁlter. The ﬁltrate was concen-
trated and the residue was treated with 0.01 M aq. NaOH (2 mL)
at ambient temperature for 3 h. The solution was neutralized by
addition of DOWEX 50 H+ resin. The ion-exchange resin was ﬁl-
tered off and the ﬁltrate was lyophilized. Puriﬁcation of the residue
on a PD10 column (H2O) and freeze-drying of pooled fractions gave
40 (2.9 mg, 92%) as a colorless amorphous solid; ½a20D +128.1 (c
0.25, H2O); 1H NMR (D2O): d 5.13 (d, 1H, J10 ,20 3.9 Hz, H-10), 4.21–
4.19 (m, 1H, H-5), 4.15–4.10 (m, 2H, H-50, H-7), 4.01 (app. t, 1H,
J4,3 = J4,5 3.3 Hz, H-4), 3.95 (dd, 1H, J8a,8b 11.8, J8a,7 2.8 Hz, H-8a),
3.85 (dd, 1H, J3,5 0.9 Hz, H-3), 3.81 (dd, 1H, J60a,60b 12.5, J60a,50
3.6 Hz, H-60a), 3.75 (dd, 1H, J60b,50 2.4 Hz, H-60b), 3.69 (dd, 1H, J8b,7
B. Pokorny et al. / Carbohydrate Research 391 (2014) 66–81 815.9 Hz, H-8b), 3.64 (dd, 1H, J6,7 9.9, J6,5 1.0 Hz, H-6), 3.59 (dd, 1H,
J30 ,20 10.1, J30 ,40 9.2 Hz, H-30), 3.52 (dd, 1H, H-20), 3.44 (dd, 1H, J40 ,50
10.2 Hz, H-40), 3.15 (s, 3H, OCH3); 13C NMR data: see Table 1;
ESI-TOF HRMS: m/z = 453.1210; calcd for C15H26O14Na+: 453.1215.
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